



# Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

## Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,  
Opp. PCI, Ankleshwar – 393 002,  
Gujarat, India  
Tel : +91-7045456789 / 7046456789  
Web: [www.samratpharmachem.com](http://www.samratpharmachem.com)

CIN: L24230GJ1992PLC017820

## Corporate Office

701/702, Business Square,  
M. A. Road, Andheri (West),  
Mumbai – 400 058, India.  
Tel : (91-22) 26701050/1/2  
Email: [contact@samratpharmachem.in](mailto:contact@samratpharmachem.in)

**06 September 2021**

To,  
**Department of Corporate Services,  
BSE Limited**  
P J Towers,  
Dalal Street,  
Mumbai - 400 001.

Scrip Code: 530125

Dear Sir,

### **Sub: Annual General Meeting – Annual Report 2020-21**

The 29<sup>th</sup> Annual General Meeting (AGM) of the Company will be held on Thursday, September 30, 2021 at 01:00 P. M. IST through Video Conferencing / Other Audio Visual Means.

Pursuant to Regulation 34(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Annual Report of the Company along with the Notice of AGM for the financial year 2020-21 which is being sent only through electronic mode to the Members.


The Annual Report containing the Notice is also uploaded on the Company's website:  
[www.samratpharmachem.com](http://www.samratpharmachem.com)

This is for your information and records.

**For Samrat Pharmachem Limited**

**Place: Mumbai  
Dated: September 6, 2021**

**Nishant Kankaria  
Company Secretary & Compliance Officer**



# **Samrat Pharmachem Limited**

**29<sup>th</sup> Annual Report  
2020-2021**



## Mr. Rajesh Mehta

Director, Samrat Pharmachem Limited

Receiving the Award from

## Ms. Shaina NC

Fashion Designer, Politician (BJP Spokes Person)  
& Social Worker

# Recognising and honouring the champions

The Economic Times identified 19 personalities, the doers and pioneers from across industries / sectors who have contributed to the growth of the nation and the society at large. The purpose behind organizing this program was to salute and recognizes remarkable business leaders, who through strength, innovation and foresight induce positive changes. These are individuals who have dared to be different and have threaded that path to inspire others, and hence rightfully chosen as the Business Leaders of 2020-21.



# CONTENTS

<b>Sr. No.</b>	<b>Particulars</b>	<b>Page No.</b>
1	Contents	1
2	Board of Directors & General Information	2
3	Notice of Annual General Meeting	3
4	Directors' Report	15
5	Corporate Social Responsibility Activities	27
6	Secretarial Audit Report	33
7	Corporate Governance Report	39
8	Management Discussion & Analysis	62
9	Independent Auditors' Report	65
10	Balance Sheet	76
11	Profit & Loss Account	78
12	Significant Accounting Policies & Schedules to Accounts & Notes	81
13	Cash Flow Statement	107

**BOARD OF DIRECTORS**

<b>Mr. Lalit Mehta</b>	Chairman & Managing Director
<b>Mr. Rajesh Mehta</b>	Executive Director
<b>Mr. Megh Mehta</b>	Executive Director
<b>Mr. Mahendra Pipalia</b>	Independent Director
<b>Mr. Samir Kothary</b>	Independent Director
<b>Ms. Renu Dharod</b>	Independent Director

**REGISTERED OFFICE & FACTORY**

Plot No. A2/3445, GIDC, Phase 4, Ankleshwar - 393 002, Gujarat  
Tel: +91-7045456789, 7046456789 Email: [contact@samratpharmachem.in](mailto:contact@samratpharmachem.in) Web: [www.samratpharmachem.com](http://www.samratpharmachem.com)  
CIN: L24230GJ1992PLC017820

**CORPORATE OFFICE**

701/702, Business Square, M. A. Road, Andheri (West), Mumbai - 400 058  
Tel: +91 22 26701050/1/2/3

**STATUTORY AUDITORS**

**Shah & Savla LLP**  
*Chartered Accountants*  
RNJ Corporate, Jawahar Road, Ghatkopar (East), Mumbai - 400 077

**COMPANY SECRETARY & COMPLIANCE OFFICER**

Mr. Nishant Kankaria

**BANKER**

**ICICI Bank Limited**  
Sagar Avenue, S. V. Road, Andheri (West), Mumbai – 400 058

**REGISTRARS & SHARE TRANSFER AGENTS**

**Link Intime India Pvt Ltd**  
C/101, 247 Park, LBS Marg, Vikhroli (West), Mumbai - 400 083  
Tel: +91 22 49186000 Fax: +91 22 49186060 Email: [rnt.helpdesk@linkintime.co.in](mailto:rnt.helpdesk@linkintime.co.in) Web: [www.linkintime.co.in](http://www.linkintime.co.in)  
CIN: U67190MH1999PTC118368

## **NOTICE OF ANNUAL GENERAL MEETING**

NOTICE is hereby given that the **TWENTY-NINTH ANNUAL GENERAL MEETING of SAMRAT PHARMACHEM LIMITED** will be held on Thursday, September 30, 2021 at 1.00 P.M. through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") to transact the following businesses:

### **ORDINARY BUSINESS**

1. To receive, consider and adopt the Audited Financial Statements of the company for the year ended 31 March 2021, together with Directors' and Auditors' Reports thereon.
2. To appoint a Director in place of Mr. Rajesh Lalit Mehta (DIN: 00216731), who retires by rotation and, being eligible, offers himself for re-appointment.
3. **Re-appointment of Statutory Auditors of the Company**

To consider and if thought fit, to pass, the following Resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 139 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, M/s. Shah & Savla LLP, Chartered Accountants having Firm Registration No. 109364W/W100143, be and are hereby re-appointed as the Statutory Auditors of the Company to hold office for their second term of 5 (Five) years from the conclusion of this Annual General Meeting till the conclusion of 34th Annual General Meeting for the financial year 2025-26 on such remuneration and terms and conditions as set out in the explanatory statement to this Notice."

**NOTES**

1. In view of the continuing COVID-19 pandemic, the Ministry of Corporate Affairs ("MCA") has vide its circular nos. 14/2020 and 17/2020 dated April 8, 2020 and April 13, 2020 respectively, in relation to "Clarification on passing of ordinary and special resolutions by companies under the Companies Act, 2013 and the rules made thereunder on account of the threat posed by Covid-19", circular no. 20/2020 dated May 5, 2020 in relation to "Clarification on holding of annual general meeting (AGM) through video conferencing (VC) or other audio visual means (OAVM)" and Circular no. 02/2021 dated January 13, 2021 in relation to "Clarification on holding of annual general meeting (AGM) through video conferencing (VC) or other audio visual means (OAVM)" (collectively referred to as "MCA Circulars") and Securities and Exchange Board of India ("SEBI") vide its circular no. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 in relation to "Additional relaxation in relation to compliance with certain provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 – Covid-19 pandemic" and circular no. SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated January 15, 2021 in relation to "Relaxation from compliance with certain provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 due to the COVID -19 pandemic" (collectively referred to as "SEBI Circulars") permitted the holding of the Annual General Meeting ("AGM") through VC / OAVM, without the physical presence of the Members at a common venue. In compliance with the MCA Circulars and SEBI Circulars, the AGM of the members of the Company is being held through VC / OAVM. The registered office of the Company shall be deemed to be the venue for the AGM.
2. The relevant details, pursuant to Regulations 26(4) and 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India, in respect of Director seeking re-appointment at this AGM are also annexed to this Notice.
3. Pursuant to the provisions of the Companies Act, 2013 ("Act") a Member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote on his / her behalf and the proxy need not be a Member of the Company. Since this AGM is being held pursuant to the MCA Circulars and SEBI Circulars through VC / OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxies by the Members will not be available for the AGM and hence the Proxy Form, Attendance Slip and route map of the AGM are not annexed to this Notice.
4. Institutional / Corporate shareholders (i.e. other than individuals, HUF, NRI, etc.) are required to send a scanned copy (PDF / JPG Format) of their respective Board or governing body Resolution / Authorization etc., authorizing their representative to attend the AGM through VC / OAVM on their behalf and to vote through remote e-Voting. The said Resolution / Authorization shall be sent to the Scrutinizer by e-mail on its registered e-mail address to [contact@samratpharmachem.in](mailto:contact@samratpharmachem.in) with a copy marked to [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in).
5. The Register of Members and Share Transfer Books will remain closed for a period of 8 days from Thursday, September 23, 2021 to Thursday, September 30, 2021 (both days inclusive) for the purpose of AGM.
6. To support the 'Green Initiative', members who have not registered their e-mail addresses are requested to register the same with M/s. Link Intime India Pvt. Ltd. / Depositories.

7. As per Regulation 40 of SEBI Listing Regulations, as amended, securities of listed companies can be transferred only in dematerialized form with effect from, April 1, 2019, except in case of request received for transmission or transposition and relogged transfers of securities. Further, SEBI vide its circular no. SEBI/HO/MIRSD/RTAMB/CIR/P/2020/236 dated December 2, 2020 had fixed March 31, 2021 as the cut-off date for re-lodgement of transfer deeds and the shares that are re-lodged for transfer shall be issued only in demat mode. In view of this and to eliminate all risks associated with physical shares and for ease of portfolio management, members holding shares in physical form are requested to consider converting their holdings to dematerialized form. Members can contact the Company or Company's Registrars and Transfer Agents, M/s. Link Intime India Pvt. Ltd. for assistance in this regard.
8. As per the provisions of Section 72 of the Act, the facility for making nomination is available for the Members in respect of the shares held by them. Members who have not yet registered their nomination are requested to register the same by submitting Form No. SH-13. The said form can be downloaded from the Company's website <https://www.samratpharmachem.com/wp-content/uploads/2021/08/Nomination-form-for-Shareholders-FORM-SH-13.pdf>. Members are requested to submit the said details to their DP in case the shares are held by them in electronic form and to Link Intime India Pvt. Ltd. in case the shares are held in physical form.
9. Members holding shares in physical form, in identical order of names, in more than one folio are requested to send to the Company or Link Intime India Pvt. Ltd., the details of such folios together with the share certificates for consolidating their holdings in one folio. A consolidated share certificate will be issued to such Members after making requisite changes.
10. In case of joint holders, the Member whose name appears as the first holder in the order of names as per the Register of Members of the Company will be entitled to vote during the AGM.
11. Members seeking any information with regard to the financial statements or any matter to be placed at the AGM, are requested to write to the Company on or before September 23, 2021 through e-mail on [contact@samratpharmachem.in](mailto:contact@samratpharmachem.in). The same will be replied by the Company suitably.
12. Members holding shares in physical form are requested to intimate the Registrar and Transfer Agent ("RTA") of the Company viz., Link Intime India Private Limited, C101, 247 Park, LBS Marg, Vikhroli (West), Mumbai 400 083 immediately of any change in their name, registered address along with pin code number, email address, telephone / mobile number, Permanent Account Number ("PAN"), mandates, nominations, power of attorneys, bank details such as name of the bank and branch details, bank account number, MICR code, IFSC code, etc. and relevant evidences.  
  
Members holding shares in electronic form shall update such details with their respective Depository Participant ("DP").
13. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
14. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.



15. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs dated April 08, 2020, April 13, 2020 and May 05, 2020 the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-voting system as well as venue voting on the date of the AGM will be provided by NSDL.
16. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM has been uploaded on the website of the Company at [www.samratpharmachem.com](http://www.samratpharmachem.com). The Notice can also be accessed from the websites of the Stock Exchange i.e. BSE Limited at [www.bseindia.com](http://www.bseindia.com) and the AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
17. The Board of Directors has appointed Mr. Aqueel A. Mulla of M/s. A. A. Mulla & Associates, Practising Company Secretary (Membership No. FCS 2973) as the Scrutinizer to scrutinize the voting during the AGM and remote e-voting process in a fair and transparent manner.

Instructions for e-voting and joining the AGM are as follows:

**THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING ARE AS UNDER:-**

The remote e-voting period begins on Monday, September 27, 2021 at 9:00 A.M. and ends on Wednesday, September 29, 2021 at 5:00 P.M. During this period, Members holding shares either in physical form or in dematerialized form, as on Thursday, September 23, 2021 i.e. cut-off date, may cast their vote electronically. The remote e-voting module shall be disabled by NSDL for voting thereafter.

The Members who have cast their vote by remote e-voting prior to the AGM may also attend/ participate in the AGM through VC / OAVM but shall not be entitled to cast their vote again.

**How do I vote electronically using NSDL e-Voting system?**

*The way to vote electronically on NSDL e-Voting system consists of “Two Steps” which are mentioned below:*

**Step 1: Log-in to NSDL e-Voting system at <https://www.evoting.nsdl.com/>**

**Step 2: Cast your vote electronically on NSDL e-Voting system.**

**Details on Step 1 is mentioned below:**

**I. Login method for remote e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.**

Pursuant to SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020 on “e-Voting facility provided by Listed Companies”, e-Voting process has been enabled to all the individual demat account holders, by way of single login credential, through their demat accounts / websites of Depositories / DPs in order to increase the efficiency of the voting process. Individual demat account holders would be able to cast their vote without having to register again with the e-Voting service provider (ESP) thereby not only facilitating seamless authentication but also ease and convenience of participating in e-Voting process.

Shareholders are advised to update their mobile number and e-mail ID with their DPs in order to access e-Voting facility.

Type of Shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL	<p><b>A NSDL IDeAS facility</b>  <b>If you are already registered, follow the below steps:</b></p> <ol style="list-style-type: none"> <li>1. Visit the e-Services website of NSDL. Open web browser by typing the following URL: <a href="https://eservices.nsdl.com/">https://eservices.nsdl.com/</a> either on a Personal Computer or on a mobile.</li> <li>2. Once the home page of e-Services is launched, click on the “<b>Beneficial Owner</b>” icon under “<b>Login</b>” which is available under “<b>IDeAS</b>” section.</li> <li>3. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services.</li> <li>4. Click on “Access to e-Voting” appearing on the left hand side under e-Voting services and you will be able to see e-Voting page.</li> <li>5. Click on options available against company name or <b>e-Voting service provider - NSDL</b> and you will be re-directed to NSDL e-Voting website for casting your vote during the remote e-Voting period or joining virtual meeting and e-Voting during the meeting.</li> </ol> <p><b>If you are not registered, follow the below steps:</b></p> <ol style="list-style-type: none"> <li>1. Option to register is available at <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a>.</li> <li>2. Select “Register Online for IDeAS” Portal or click at <a href="https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp">https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp</a></li> <li>3. Please follow steps given in points 1-5.</li> </ol> <p><b>B e-Voting website of NSDL</b></p> <ol style="list-style-type: none"> <li>1. Open web browser by typing the following URL: <a href="https://www.evoting.nsdl.com/">https://www.evoting.nsdl.com/</a> either on a personal computer or on a mobile phone.</li> <li>2. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section.</li> <li>3. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number held with NSDL), Password / OTP and a Verification Code as shown on the screen.</li> <li>4. After successful authentication, you will be redirected to NSDL website wherein you can see e-Voting page. Click on options available against company name or e-Voting service provider - NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting and e-Voting during the meeting.</li> </ol>
Individual Shareholders holding securities in demat mode with CDSL	<ol style="list-style-type: none"> <li>1. Existing users who have opted for Easi / Easiest, can login through their user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest is <a href="https://web.cdslindia.com/myeasi/home/login">https://web.cdslindia.com/myeasi/home/login</a> or <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on New System Myeasi.</li> <li>2. After successful login of Easi / Easiest the user will be also able to see the e-Voting Menu. The Menu will have links of ESP i.e. NSDL portal. Click on NSDL to cast your vote.</li> </ol>

	3. If the user is not registered for Easi/Easiest, option to register is available at <a href="https://web.cdslindia.com/myeasi/Registration/">https://web.cdslindia.com/myeasi/Registration/</a> EasiRegistration. Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN from a link in <a href="http://www.cdslindia.com">www.cdslindia.com</a> home page. The system will authenticate the user by sending OTP on registered Mobile and e-mail as recorded in the demat Account. After successful authentication, user will be provided links for the respective ESP i.e. NSDL where the e-Voting is in progress.
Individual Shareholders (holding securities in demat mode) logging through their depository participants	<ol style="list-style-type: none"> <li>1. You can also login using the login credentials of your demat account through your DP registered with NSDL / CDSL for e-Voting facility.</li> <li>2. Once logged-in, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL / CDSL Depository site after successful authentication, wherein you can see e-Voting feature.</li> <li>3. Click on options available against company name or e-Voting service provider - NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting and e-Voting during the meeting.</li> </ol>

**Important note:** Members who are unable to retrieve User ID / Password are advised to use Forgot User ID and Forgot Password option available at respective websites.

**Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL**

Login type	Helpdesk details
Securities held with NSDL	Please contact NSDL helpdesk by sending a request at <a href="mailto:evoting@nsdl.co.in">evoting@nsdl.co.in</a> or call at toll free no.: 1800 1020 990 and 1800 22 44 30
Securities held with CDSL	Please contact CDSL helpdesk by sending a request at <a href="mailto:helpdesk.evoting@cdslindia.com">helpdesk.evoting@cdslindia.com</a> or contact at 022- 23058738 or 022-23058542-43

## II. Login method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a personal computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under "Shareholders / Member" section
3. A new screen will open. You will have to enter your User ID, your Password / OTP and a Verification Code as shown on the screen.
4. Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. cast your vote electronically.

5. Your User ID details are given below:

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
A) For Members who hold shares in demat account with NSDL	8 Character DP ID followed by 8 Digit Client ID For example, if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****
B) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example, if your Beneficiary ID is 12***** then your user ID is 12*****
C) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example, if EVEN is 123456 and folio number is 001*** then user ID is 123456001***

6. Your password details are given below:

- A) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
  - B) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you by NSDL. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
  - C) How to retrieve your 'initial password'?
    - i) If your e-mail ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your e-mail ID. Trace the e-mail sent to you from NSDL in your mailbox from evoting@nsdl.com. Open the e-mail and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8-digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
    - ii) In case you have not registered your e-mail address with the Company / Depository, please follow instructions mentioned below in this notice.
7. If you are unable to retrieve or have not received the 'initial password' or have forgotten your password:
- a) Click on "Forgot User Details / Password?" (If you are holding shares in your demat account with NSDL or CDSL) option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
  - b) "Physical User Reset Password?" (If you are holding shares in physical mode) option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
  - c) If you are still unable to get the password by aforesaid two options, you can send a request at [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in) mentioning your demat account number / folio number, your PAN, your name and your registered address
  - d) Members can also use the one-time password (OTP) based login for casting the votes on the e-Voting system of NSDL
8. After entering your password, click on Agree to "Terms and Conditions" by selecting on the check box
9. Now, you will have to click on "Login" button
10. After you click on the "Login" button, Home page of e-Voting will open.

Details on Step 2 is mentioned below:

**How to cast your vote electronically on NSDL e-Voting system?**

1. After successful login at Step 1, you will be able to see all the companies “EVEN” in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select “EVEN” of company for which you wish to cast your vote.
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on “Submit” and also “Confirm” when prompted.
5. Upon confirmation, the message “Vote cast successfully” will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

**General Guidelines for shareholders**

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to [contact@samratpharmachem.in](mailto:contact@samratpharmachem.in) with a copy marked to [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in)
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the “Forgot User Details/Password?” or “Physical User Reset Password?” option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com) to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of [www.evoting.nsdl.com](http://www.evoting.nsdl.com) or call on toll free no.: 1800-222-990 or send a request to Mr. Nipul Shah at [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in)

**Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:**

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to [contact@samratpharmachem.in](mailto:contact@samratpharmachem.in)

**THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM ARE AS UNDER:-**

1. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.
3. Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.
4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

**INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:**

1. Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access the same at <https://www.evoting.nsdl.com> under shareholders/members login by using the remote e-voting credentials. The link for VC/OAVM will be available in shareholder/members login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush. Further members can also use the OTP based login for logging into the e-Voting system of NSDL.
2. Members are encouraged to join the Meeting through Laptops for better experience.
3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
5. Members who would like to express their views/have questions during the meeting may register themselves as speakers and/or may send their questions/ request seven (7) days prior to meeting mentioning their name demat account number/folio number, email id, mobile number at [contact@samratpharmachem.in](mailto:contact@samratpharmachem.in)  
The same will be replied by the company suitably.

**Other Instructions:**

1. The voting rights of Members shall be in proportion to their shares in the paid-up equity share capital of the Company as on the cut-off date i.e. Thursday, September 23, 2021.
2. Any person, who acquires shares of the Company and becomes a Member of the Company after sending of the Notice and holding shares as of the cut-off date, may obtain the login ID and password by sending a request at [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in). However, if he/she is already registered with NSDL for remote e-voting then he/she can use his / her existing User ID and password for casting the vote.

3. The Scrutinizer shall, immediately after the conclusion of voting at the AGM, first count the votes cast during the AGM, thereafter unblock the votes cast through remote e-voting and make, within a period not exceeding two (2) working days from the conclusion of the AGM, a consolidated Scrutinizers Report of the total votes cast in favour or against if any, to the Chairman of the Company who shall countersign the same.
4. The results declared along with the Scrutinizer's Report will be posted on the company's website [www.samratpharmachem.com](http://www.samratpharmachem.com) and on the website of NSDL <https://www.evoting.nsdl.com> within two (2) days of the passing of the resolutions at the 29th AGM of the Company on Thursday, September 30, 2021 and shall be communicated to BSE Limited ("BSE"), where the shares of the Company are listed.

**Place : Mumbai**  
**Date : 30 June 2021**

**By order of the Board of Directors  
For Samrat Pharmachem Limited**

**Lalit Mehta**  
**Chairman & Managing Director**  
**DIN : 00216681**

**ANNEXURE TO THE NOTICE**  
**Explanatory Statement**

Pursuant to section 102 of the Companies Act

As required by Section 102 of the Companies Act, 2013 (Act), the following explanatory statements set out all material facts relating to the business mentioned under Item No. 3 accompanying Notice:

**Item No. 3**

M/s. Shah & Savla LLP., Chartered Accountants were appointed as the Statutory Auditors of the Company from the conclusion of 24th Annual General Meeting held on September 23, 2017 for a period of five years, from financial year 2016-17 to 2020-21. Their term of office shall be completed at the conclusion of the 29th AGM to be held on 30th September, 2021. They are eligible for second term as per the provision of Section 139 of the Companies Act, 2013 and rules made there under.

M/s. Shah & Savla LLP., Chartered Accountants have expressed their willingness to act as Statutory Auditors of the Company for a period of 5 (Five) years as per the requirement of Sec 139 of the Companies Act, 2013 and rules made thereunder.

Terms and Conditions of Re-appointment are as under:

Term of Appointment:

5 year from the conclusion of this AGM till the conclusion of AGM for FY 2025-26

Proposed Fees:

The remuneration for Statutory Audit plus applicable taxes, travelling and other out-of-pocket expenses of the Company as may be mutually decided by the Auditors of the Company and the Board of Directors of the Company. The remuneration will be based on knowledge, expertise, industry experience, time and efforts required to be put in by M/s. Shah & Savla LLP. during their association with the Company. The proposed fee will also be in line with the industry benchmarks. The fees for services in the nature of limited review, statutory certifications and other professional work will be in addition to the audit fee as above and will be decided by the management in consultation with the Auditors.

Credentials:

Shah & Savla LLP is an old and well established Chartered Accountancy firm, having been setup on June 6, 2016. The firm is head-quartered in Mumbai with its operations adequately supported by qualified professionals and staff. Apart from statutory audit, the firm also has expertise in other allied areas.

The firm has been statutory auditors of Midcap listed companies to cross section of industries and carries a good professional track-record.

The Board of Directors recommends the Ordinary Resolution as set out in Item No. 3 of the Notice for approval by the Members.

None of the Directors, Key Managerial Personnel and relatives thereof has any concern or interest, financial or otherwise in thereof has any concern or interest, financial or otherwise in the resolution at Item No. 3 of this Notice.

**By order of the Board of Directors**  
**For Samrat Pharmachem Limited**

**Place : Mumbai**  
**Date : 30 June 2021**

**Lalit Mehta**  
**Chairman & Managing Director**  
**DIN : 00216681**



## Annexure A

**Details of Directors seeking re-appointment at the Annual General Meeting scheduled to be held on September 30, 2021**

[Pursuant to Regulation 36(3) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015].

<b>Name of the Director</b>	<b>Rajesh Lalit Mehta (DIN: 00216731)</b>
<b>Date of birth</b>	25.06.1964
Age	57 years
Date of Appointment	16.06.1992
Relationship with Directors	Relative: Son of Mr. Lalit Mehta Father of Mr. Megh Mehta
Expertise in specific functional area	Wide experience in Finance, Corporate Affairs & MIS
Qualification(s)	<ul style="list-style-type: none"> <li>• Bachelor's Degree of Commerce (BCom)</li> <li>• Chartered Accountant (CA)</li> </ul>
Directorships held in other listed companies	Nil
Chairmanships/ Memberships of Committees of other public companies (includes only Audit Committee And Stakeholders Relationship Committee)	Nil
Number of shares held in the Company as on March 31, 2021	381,042

**Notes:**

1. The Directorship, Committee Memberships and Chairmanships do not include positions in foreign companies, unlisted companies and private companies, position as an Advisory Board Member and position in companies under Section 8 of the Companies Act, 2013.
2. The proposal for re-appointments of Directors has been approved by the Board pursuant to the recommendation of the Board Governance, Nomination and Compensation Committee considering their skills, experience and knowledge and positive outcome of performance evaluation.
3. Information pertaining to remuneration paid to the Directors who are being re-appointed and the number of Board Meetings attended by them during the year 2020-21 are provided in the Corporate Governance Report.
4. For other details such as number of meetings of the board attended during the year, remuneration drawn, please refer to the corporate governance report which is a part of this Annual Report.

**DIRECTORS' REPORT**

To,  
**The Members**  
 Samrat Pharmachem Limited

The Directors are pleased to present the 29th Annual Report on the business and operations of the company and the financial accounts for the year ended 31 March 2021

**FINANCIAL PERFORMANCE**

<i>Particulars</i>	<b>31 March 2021 Rs.</b>	<b>31 March 2020 Rs.</b>
<i>Revenue from Operations</i>	<b>1,790,177,828</b>	1,374,524,757
<i>Other Income</i>	<b>4,628,134</b>	5,721,509
<i>Total Revenue</i>	<b>1,794,805,962</b>	1,380,246,267
<i>Earnings before Interest, Tax, Depreciation &amp; Amortisation (EBITDA)</i>	<b>91,311,135</b>	72,015,965
<i>Interest and Finance Charges</i>	<b>12,766,728</b>	9,783,321
<i>Profit / (Loss) before Depreciation, Exceptional Items and Tax</i>	<b>78,544,407</b>	62,232,644
<i>Depreciation</i>	<b>4,928,617</b>	4,262,541
<i>Exceptional Items</i>	<b>176,807</b>	120,212
<i>Profit / (Loss) before Tax (PBT)</i>	<b>73,615,791</b>	57,970,102
<i>Provision for Tax / Tax expense</i>	<b>20,107,195</b>	15,482,386
<i>Profit / (Loss) after Tax (PAT)</i>	<b>53,508,596</b>	42,487,716
<i>Earnings Per Share (Basic EPS)</i>	<b>17.26</b>	13.71

**Other Financial Disclosures**

There were no material changes and commitments affecting the financial position of the Company which occurred between the end of the financial year to which this financial statement relates on the date of this Report.

During the financial year, there was no amount proposed to be transferred to the Reserves. Capital Expenditure during the year was at Rs. 272 Lakhs (*Rs. 76 Lakhs in the previous year*).

During the year, your Company did not accept any public deposits under Chapter V of the Companies Act, 2013.

Your Company manages cash and cash flow processes assiduously, involving all parts of the business. There was a net cash surplus of 2.12 lakhs (*financial year 2019-20 : - 124.54 Lakhs*), as on 31st March, 2021. The Company's low debt equity ratio provides ample scope for gearing the Balance Sheet, should the need arise. Foreign Exchange transactions are fully covered with strict limits placed on the amount of uncovered exposure, if any, at any point in time. There are no materially significant uncovered exchange rate risks in the context of Company's imports and exports. The Company accounts for mark-to-market gains or losses every quarter end, are in line with the requirements of Ind AS 21. The details of foreign exchange earnings and outgo as required under Section 134 of the Companies Act, 2013 and Rule 8(3) of Companies (Accounts) Rules, 2014 are mentioned below:

Particulars	FY 2020-21	FY 2019-20
Foreign exchange earning	136,618,822.73	69,278,295.00
Foreign exchange outgo	1,334,152,735.89	1,115,437,893.00

### Covid-19 Pandemic

The COVID-19 Pandemic has affected the industrial environment throughout the financial year 2020-21. The volume of business affected by the pandemic vary in different industries. The tourism, airlines, transport, real estate & retail have been badly affected by COVID 19 pandemic other industries too have reciprocal effect. In case of pharmaceutical industry the effect was minimum. The company had taken all measures of safety for its workers & employees. The working/operation has remained smooth during the new normal. Since the company manufactures pharmaceutical intermediateries it was exempted for restrictions and was not much affected by lockdown & travel restrictions.

The Company further initiated safety measures by vaccinating its workers & employees to achieve safety level. So far maximum workers and employees have been vaccinated with 1st dose and some have completed both doses. The COVID 19 pandemic had no major impact on the sales of the company. The measures initiated by the company will help overcome the pandemic situation and company expects normal operation growth & profitability in FY 2021-22.

### OPERATIONS

Your company has performed extremely well during the year. In a highly competitive, uncertain and volatile business environment, your Company achieved a turnover of Rs. 17902 Lakhs as against Rs. 13745 Lakhs achieved last year - an increase of more than 30%.

### DIVIDEND

In order to conserve the resources, your Directors do not recommend payment of Dividend for the financial year ended 31st March, 2021.

### TRANSFER OF AMOUNTS TO INVESTOR EDUCATION & PROTECTION FUND

Your Company did not have any funds lying unpaid or unclaimed for a period of seven years. Therefore, there were no funds which were required to be transferred to Investor Education & Protection Fund.

**EXPORTS**

During the year 2020-21 your company's export division registered FOB sales of Rs. 1366 Lacs from Rs. 693 Lacs achieved last year. Your Company has initiated several export promotion measures to increase exports. The products of your Company have been well accepted in the international market and the Company expects better export turnover in the coming years.

**DEMATERIALISATION**

The equity shares of the Company have been dematerialized by joining the depositories viz. National Securities Depository Limited (NSDL) & Central Depository Services (India) Limited (CDSL). The ISIN (International Securities Identification Number) No. allotted to the Company is INE103E01016.

**LISTING OF SHARES**

The Company's shares are listed on the BSE Ltd. It has paid the listing fees of the said exchange for the period upto 31st March, 2022. Your Company has not been delisted on this exchange for non-payment of listing fees.

**INSURANCE**

The assets of the company have been adequately insured against all possible risks with ICICI Lombard General Insurance Co Ltd

**WEBSITE**

Your company's website address is [www.samratpharmachem.com](http://www.samratpharmachem.com). The performance of the Company is regularly updated and made available on this website. The website provides other vital information about the Company.

**SAFETY, HEALTH & ENVIRONMENT (SHE) POLICY**

As a responsible corporate citizen, the Company is fully aware of its responsibilities for protection of the environment and to provide its employees a safe and hazard free work place. The Company has adopted a Safety, Health & Environment Policy that applies to all employees and activities. The work culture encourages total involvement and commitment of the employees to the SHE Policy.

Some of the activities carried out during the year are as follows.

**Safety:**

- Providing necessary equipment's and apparatus required for the safe operation of the manufacturing activities
- Observing the rules and regulations with regard to safety & precaution
- Consulting emergency control management team to monitor the safety of the plant
- Conducting regular safety audit
- Encouraging the workforce to use protective equipment's and maintain cleanliness
- Conducting seminars to impart knowledge to employees on safe operations
- Organising safety week to create safety awareness

**Health:**

- Conducting medical health check up for all the employees of the Company periodically
- Conducting lecture meetings for providing guidance and counselling on matters of health, diet and exercise
- Conducting seminars to impart knowledge on meditation, yoga and anti-stress therapy

**Environment:**

- Ensuring smooth functioning of the effluent treatment plant with respect to air, water and solid waste.
- Updating the ETP plant to make it more nature friendly
- Proper monitoring of the pollution levels in and around the plants
- Planting trees in and around the factory
- Complying with the prescribed norms of pollution control

**PERSONNEL**

As on 31<sup>st</sup> March 2021, the total number of employees on the payroll of the company were 27. Industrial relations with employees at various levels continue to be cordial.

**DIRECTORS & KEY MANAGERIAL PERSONNEL**

In pursuance to the provisions of the Companies Act, 2013, and Articles of Association of the company Mr. Rajesh Mehta, Director retires by rotation and being eligible has offered himself for re-appointment.

As per the provisions of the Act, the Independent Directors are not liable to retire by rotation. The Independent Directors of your Company have given the certificate of independence to your Company stating that they meet the criteria of independence as mentioned under Section 149(6) of the Companies Act, 2013 and the Listing Regulations. The details of training and familiarization program and Annual Board Evaluation process for Directors have been provided in the Corporate Governance Report. The policy on Director's appointment and remuneration including criteria for determining qualifications, positive attributes, independence of Director, and also remuneration for key managerial personnel and other employees, forms part of the Corporate Governance Report of this Annual Report.

The company has received declaration from all the independent directors confirming that they meet the criteria of independence as prescribed under section 149(6) of the Companies Act, 2013.

The company has devised a policy for the performance evaluation of independent directors, Board committees and other individual directors which include criteria for performance evaluation of non-executive directors and executive directors. The manner in which the evaluation is carried out has been explained in the Corporate Governance Report.

**SUBSIDIARIES, JOINT VENTURES OR ASSOCIATE COMPANIES**

Your company has no subsidiaries, joint ventures or any associate companies during the year.

**MEETING OF THE BOARD**

During the year under review 6 Board Meetings were held. The intervening gap between the meetings was within the period prescribed under the Companies Act, 2013. For further details please refer to the Corporate Governance Report attached to this Annual Report.

**AUDIT COMMITTEE**

The Audit Committee comprises of the 3 Directors namely, Mr. Mahendra Pipalia (Chairman) and Mr. Samir Kothary and Ms. Renu Dharod as other members of the committee.

This committee recommends and reviews the unaudited & audit financial results. It also recommends the appointment / re-appointment of Statutory Auditor, Tax Auditor & GST Auditor. It also oversees whistle blower policy and makes recommendation to the Board from time to time. The committee also guides the Board for improving MIS systems, digitalising business operations and making all operations online & law compliant. The Board has accepted all recommendations made by the audit committee during the year.

**NOMINATION AND REMUNERATION COMMITTEE**

The Nomination and Remuneration Committee comprises of the 3 Directors namely, Mr. Samir Kothary (Chairman), and Mr. Mahendra Pipalia and Ms. Renu Dharod as other members of the committee.

This committee recommends and reviews the appointment and remuneration of Directors. It has adopted a policy which deals with the appointment and remuneration of directors and key managerial personnel. The adopted policy decides about the manner of selection of executive directors, key managerial personnel, and independent directors. The policy also decides about the criteria to be followed for recommending the remuneration of directors and key managerial personnel.

**STAKEHOLDERS RELATIONSHIP COMMITTEE**

The Stakeholders Relationship Committee comprises of the 3 Directors namely, Ms. Renu Dharod (Chairperson) and Mr. Mahendra Pipalia and Mr. Samir Kothary as other members of the committee.

The committee reviews investor services, reviews work done by the share transfer agent including adherence to the service standards & resolve investor grievance. The committee also advises the company on various shareholders' related matters.

**RISK MANAGEMENT COMMITTEE**

The Risk Management Committee comprises of the 3 Directors namely, Ms. Renu Dharod (Chairperson) and Mr. Mahendra Pipalia and Mr. Samir Kothary as other members of the committee.

The risk management committee of the board oversees and reviews the risk management framework as well as the assessment of risks, their management and mitigation procedures. They also discuss with senior management regarding enterprise risk management (ERM) and management of cyber security risks. They also assess business risk, credit risk, disaster management and proper coverage of insurance of the fixed assets of the Company including their safety and security.

**HEALTH, SAFETY AND SUSTAINABILITY COMMITTEE**

The Health, Safety and Sustainability Committee comprises of the 3 Directors namely, Ms. Renu Dharod (Chairperson) and Mr. Mahendra Pipalia and Mr. Samir Kothary as other members of the committee.

The Committee establishes with management long term environmental and social sustainability, health and safety goals and evaluate the Company's progress against those goals and report to the Board. It also considers and advises management of emerging environmental and social sustainability issues that may affect the business, performance or reputation of the Company and make recommendations, as appropriate, on how management can address such issues;

The committee monitors the company's risk management processes related to environmental and social sustainability, health and safety with particular attention to managing and minimising environmental risks and impacts. The Committee also advises the management on implementing, maintaining and improving environmental and social sustainability, health and safety strategies, implementation of which creates value consistent with long term preservation and enhancement of shareholder value.

It also reviews handling of incident reports, pollution control measures, results of investigations into material events, findings from environmental and social sustainability, health and safety audits and the action plans proposed pursuant to the findings.

**CONSTITUTION OF CSR COMMITTEE**

The Company has constituted CSR Committee which comprises of 6 Directors namely, Mr. Lalit Mehta, Mr. Rajesh Mehta, Mr. Megh Mehta, Mr. Mahendra Pipalia, Mr. Samir Kothary & Ms. Renu Dharod. The Chairperson of the Committee is Ms. Renu Dharod.

The Committee formulates, reviews and recommends to the Board, a CSR policy indicating the activities to be undertaken by the Company as specified in schedule VII of the Companies Act, 2013;

The brief outline of the corporate social responsibility (CSR) policy of the Company and the initiatives undertaken by the Company on CSR activities during the year are set out in **Annexure I** of this report in the format prescribed in the Companies (Corporate Social Responsibility Policy) Rules, 2014. For other details regarding the CSR Committee, please refer to the Corporate Governance Report, which is a part of this report. This Policy is available on the Company's website [www.samratpharmachem.com](http://www.samratpharmachem.com)

**BOARD EVALUATION**

The Board of Directors have carried out an annual evaluation of its own performance, Board Committees and individual directors pursuant to the provision of Act and the Corporate Governance requirement as prescribed by Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements), Regulations 2015 ("SEBI Listing Regulations"). The performance of Board was evaluated by the Board of Directors after seeking inputs from all directors on the basis of criteria such as Board Composition & Structure, Effectiveness of Board Process, Information and functioning, etc.

In separate meeting of Independent directors' performance of Non-Independent Directors, performance of the Board as whole and performance of Chairman was evaluated, taking into account the views of executive directors and non-executive directors.

**POLICIES**

We seek to promote and follow the highest level of ethical standards in all our business transactions guided by our value system. The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 mandated the formulation of certain policies for all listed companies. All our corporate governance policies are available on our website ([www.samratpharmachem.com](http://www.samratpharmachem.com)). These policies are reviewed periodically by the Board and updated based on need and new compliance requirement.

Policies adopted by the Company:

Name of the policy	Web link
Archival Policy	<a href="http://www.samratpharmachem.com/archival-policy/">http://www.samratpharmachem.com/archival-policy/</a>
Appointment of Independent Directors Policy	<a href="https://www.samratpharmachem.com/independent-director-terms-and-conditions-of-appointment/">https://www.samratpharmachem.com/independent-director-terms-and-conditions-of-appointment/</a>
Related Party Transactions & its Materiality Policy	<a href="https://www.samratpharmachem.com/policy-on-related-party-transactions-and-its-materiality/">https://www.samratpharmachem.com/policy-on-related-party-transactions-and-its-materiality/</a>
Whistle-blower Policy	<a href="https://www.samratpharmachem.com/whistleblower-policy/">https://www.samratpharmachem.com/whistleblower-policy/</a>
Materiality of Events Policy	<a href="https://www.samratpharmachem.com/materiality-of-events-policy/">https://www.samratpharmachem.com/materiality-of-events-policy/</a>
Preservation of Documents Policy	<a href="https://www.samratpharmachem.com/policy-on-preservation-of-documents/">https://www.samratpharmachem.com/policy-on-preservation-of-documents/</a>
Insider Trading Policy	<a href="https://www.samratpharmachem.com/insider-trading-policy/">https://www.samratpharmachem.com/insider-trading-policy/</a>
Privacy Policy	<a href="https://www.samratpharmachem.com/privacy-policy/">https://www.samratpharmachem.com/privacy-policy/</a>
Quality Policy	<a href="https://www.samratpharmachem.com/quality-policy-2/">https://www.samratpharmachem.com/quality-policy-2/</a>
Safety, Health & Environment (SHE) Policy	<a href="http://www.samratpharmachem.com/policies/she-policy/">http://www.samratpharmachem.com/policies/she-policy/</a>
Corporate Social Responsibility Policy	<a href="http://www.samratpharmachem.com/policies/corporate-social-policy/">http://www.samratpharmachem.com/policies/corporate-social-policy/</a>
Fair Code For Insider Trading Policy	<a href="https://www.samratpharmachem.com/fair-code-for-insider-trading/">https://www.samratpharmachem.com/fair-code-for-insider-trading/</a>
Inquiry Leak of UPSI	<a href="https://www.samratpharmachem.com/inquiry-leak-of-upsi/">https://www.samratpharmachem.com/inquiry-leak-of-upsi/</a>
Remuneration Policy	<a href="https://www.samratpharmachem.com/remuneration-policy/">https://www.samratpharmachem.com/remuneration-policy/</a>
Code of Conduct for Prohibition of Insider Trading	<a href="https://www.samratpharmachem.com/9740-2/">https://www.samratpharmachem.com/9740-2/</a>
Legitimate Purposes Policy for sharing UPSI	<a href="https://www.samratpharmachem.com/legitimate-purposes/">https://www.samratpharmachem.com/legitimate-purposes/</a>



**REMUNERATION RATIO OF THE DIRECTORS / KEY MANAGERIAL PERSONNEL (KMP) / EMPLOYEES**

The information required under Section 197 of the Act read with rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are given below:

((₹) lakh)					
Sr. No.	Name & Designation	Remuneration Paid FY 2020-21	Remuneration Paid FY 2019-20	Increase in remuneration from previous year	Ratio/Times per Median of employee remuneration
1	Mr. Lalit Mehta <i>Chairman &amp; Managing Director</i>	1,800,000	1,800,000	0	8.82
2	Mr. Rajesh Mehta <i>Executive Director</i>	1,740,000	1,740,000	0	8.53
3	Mr. Megh Mehta <i>Executive Director</i>	900,000	900,000	0	4.41
4	Mr. Nishant Kankaria <i>Company Secretary</i>	198,800	0	0	0.82

For more information on the remuneration of Executive Directors & KMP, please refer to the **Annexure II** to the Directors Report

**DIRECTORS' RESPONSIBILITY STATEMENT**

Pursuant to Section 134(5) of the Companies Act, 2013, the Board of Directors report that: -

1. That the preparation of accounts for the Financial Year ended 31st March 2021, the applicable accounting standards read with requirements set out under Schedule III of the Act, have been followed along-with proper explanation relating to material departures;
2. That the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that were reasonable and prudent so as to give true and fair view of the state of affairs of the Company at the end of the Financial Year and the Profit or Loss of the Company for the year on that date;
3. That the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
4. That the Directors' have prepared the accounts for the financial year ended 31st March 2021 on a going concern basis.
5. That the Directors have laid down internal financial control to be followed by the company and that such internal financial controls are adequate and are operating effectively; and
6. That the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such system are adequate and operating effectively

Based on the framework of internal financial controls and compliance systems established and maintained by the Company, work performed by the internal, statutory and secretarial auditors and external consultants and the reviews performed by the management and the relevant board committees, including the audit committee the board is of the opinion that the company's internal financial controls were adequate and effective during the financial year 2020-21.

## **MANAGEMENT DISCUSSION & ANALYSIS REPORT**

As required under regulation 34 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, the Management Discussion and Analysis Report is enclosed as a part of this annual report.

## **CORPORATE GOVERNANCE**

A separate report on Corporate Governance is provided together with a Certificate from the Corporate Governance Auditors of the Company regarding compliance of conditions of Corporate Governance as stipulated under Listing Regulations. A Certificate of the CEO and CFO of the Company in terms of Listing Regulations, inter-alia, confirming the correctness of the financial statements and cash flow statements, adequacy of the internal control measures and reporting of matters to the Audit Committee, is also annexed to the annual report.

## **SEXUAL HARASSMENT OF WOMEN AT WORK PLACE**

During the year under review, there were no cases reported pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

The Company has complied with the applicable provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules made thereunder, including constitution of the Sexual Harassment Committee i.e. Internal Complaints Committee.:

No. of complaints filed during Financial Year 2020-21:	Nil
No. of complaints disposed off during Financial Year 2020-21:	NA
No. of complaints pending as on 31st March, 2021:	NA

## **AUDITORS**

M/s. Shah & Savla LLP, Chartered Accountants (FRN : 109364W / W100143) are to be re-appointed as Statutory Auditors of your Company, for the second term of five consecutive years. The Auditors have confirmed that they are not disqualified from being re-appointed as Auditors of the Company. The Report given by the Auditors on the financial statement of the Company is part of this Report. There has been no qualification, reservation, adverse remark or disclaimer given by the Auditors in their Report. During the year under review, the Auditors had not reported any matter under Section 143 (12) of the Companies Act, 2013.

## **AUDITORS REPORT**

The report of Statutory Auditors alongwith notes to schedules is a part of the Annual Report. There has been no qualification, reservation, adverse remark or disclaimer given by the Auditors in their report. Further there is no incident of fraud requiring reporting by Auditors under section 143(12) of the Companies Act, 2013.

**INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY:**

The Company has in place adequate internal financial control procedures commensurate with its size and the nature of business.

The Company has appointed an Internal Auditor who periodically conducts audit of the adequacy and effectiveness of the internal controls laid down by the management and suggest improvements. During the year under review, no material or serious observation has been received from the Statutory Auditors of the Company for inefficiency or inadequacy of such controls.

The Audit Committee of the Board of Directors approves the annual internal audit plan and periodically reviews the progress of audits as per approved audit plans.

**ANNUAL SECRETARIAL COMPLIANCE REPORT**

The Company has undertaken an audit for the financial year 2020-21 for all applicable compliances as per SEBI Regulations and Circulars/Guidelines issued thereunder.

**SECRETARIAL AUDITOR**

Pursuant to provisions of Section 204 of the Companies Act, 2013 and The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 the company has appointed M/s. A. A. Mulla & Associates a firm of company Secretaries in practice to undertake the Secretarial Audit of the Company for the financial year 2021-22. The Secretarial Audit Report submitted by the Secretarial Auditor is enclosed herewith as a part of this report and shown as **Annexure III**.

The Secretarial Audit Report contains qualification, reservation or adverse remark pertaining to non-compliance under SEBI (LODR) Regulations, 2015 which has been complied with & penalty imposed by BSE has been paid.

**SECRETARIAL STANDARDS**

The Company has complied with all the applicable provisions of Secretarial Standard-1 and Secretarial Standard-2 as issued by the Institute of Company Secretaries of India.

**SIGNIFICANT/MATERIAL ORDERS PASSED BY THE REGULATORS**

There are no significant/material orders passed by the Regulators or Courts or Tribunals impacting the going concern status of the Company and its operations in future.

**RELATED PARTY TRANSACTION / DISCLOSURE**

There are no related party transactions made by the company during the year. None of the transactions with related parties fall under the scope of Section 188(1) of the Act. Accordingly, the disclosure of related party transactions as required under Section 134(3)(h) of the Act in Form AOC-2 is not applicable to the Company for FY 2020-21 and hence does not form part of this report.

**ANNUAL RETURN**

Pursuant to Section 92(3) read with Section 134(3)(a) of the Act, the Annual Return as on 31st March, 2021 is available on the Company's website on <https://www.samratpharmachem.com/wp-content/uploads/2021/08/Mar-2021-MGT7.pdf>

**LOANS, GUARANTEES AND INVESTMENTS**

Details of Loans, Guarantees and Investments covered under the provisions of Section 186 of the Companies Act, 2013 are given in the notes to the Financial Statements.

**PARTICULARS OF EMPLOYEES**

Under the provision of Section 197(12) of the Companies Act, 2013 read with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel), 1956 read with Companies (Particulars of Employees) Rules, 2014, the particulars of the employees as required to be mentioned in the Annual Report is not applicable to the company.

**SHARES ISSUED UNDER EMPLOYEE STOCK OPTION SCHEME (ESOS)**

No shares have been issued to the employees under Employee Stock Option Scheme (ESOS) during the year.

**PUBLIC DEPOSITS**

The Company has not invited and accepted deposits from the public during the financial year ended 31<sup>st</sup> March 2021.

**DISCLOSURE OF PARTICULARS RELATING TO CONSERVATION OF ENERGY & TECHNOLOGY ABSORPTION**

The particulars relating to conservation of energy, technology absorption, foreign exchange earnings and outgo, as required to be disclosed pursuant to the provisions of Section 134 of the Act read with Rule 8 of the Companies (Accounts Rules), 2014, is given hereunder.

**CONSERVATION OF ENERGY AND TECHNOLOGY ABSORPTION**

Your Company continues to explore & implement measures that will help in conservation and saving of energy.

Measures taken & benefits derived are as follows:

- Hot water coming from steam traps is recycled & used as boiler feed water.
- Using economiser effectively to pre-heat boiler feed water.
- Timely & routine preventive maintenance of boiler.
- Improvement in unit operations leading to reduction in processing time in reactor, centrifuge, drier & other equipment's to minimize use of electricity.
- Hot water coming from steam traps is recycled & used as boiler feed water.

**TECHNOLOGY ABSORPTION**

The management has focused on productivity and quality improvement in order to optimize manufacturing costs. This has helped in achieving optimum manufacturing costs, improved quality of products and consequently enhanced customer satisfaction. The company uses indigenous technology.

**DISCLOSURE REQUIREMENTS**

The Company has devised proper systems to ensure compliance with the provisions of all applicable Secretarial Standards issued by the Institute of Company Secretaries of India and that such systems are adequate and operating effectively.

**ACKNOWLEDGEMENTS**

The Directors wish to place on record their appreciation towards all associates including customers, suppliers, financial institutions, bankers, employees, consultants, shareholders and to all those who have extended their committed support to the progress of the Company.

**Place :** Mumbai  
**Date :** 30 June 2021

**By order of the Board of Directors  
For Samrat Pharmachem Limited**

**Lalit Mehta  
Chairman & Managing Director  
DIN : 00216681**

## Annexure I to the Directors Report

**Annual Report On The Corporate Social Responsibility (CSR) Activities  
as on financial year ended on March 31, 2021**

[Pursuant to Section 135 of the Companies Act, 2013 and CSR rules as amended]

1. **A brief outline of the company's CSR policy, including overview of projects or programs proposed to be undertaken and a reference to the web-link to the CSR policy and projects or programs.**

Samrat Pharmachem Limited core belief is to make a meaningful and positive contribution to the society as whole by way of looking for opportunity to help the needy and ensuring environment sustainability in the long run. We strive to enrich the lives of the community at large through our CSR initiatives. To achieve our objective, we strive to implement the projects through various non-governmental organisations (NGO) partners, government bodies and other social institutions.

Our vision is to create an environment where a person with the ability to feed far exceeds the person with need. This will create a long term self sustainable and compassionate environment.

We have identified the following areas to achieve our objective although not limited to these areas alone:

- *Education to the under privileged, Contributing to skill development programmes*
- *Contributing to programmes for environmental sustainability etc.*
- *Protection of national heritage, art and culture including restoration of historical places*
- *Setting up of public library*
- *Promotion and development of traditional arts and handicrafts*
- *Training & promotion of rural sports*
- *Conservation of natural resources, forests, animal welfare & endangered wild life*
- *Eradicating hunger, poverty & malnutrition, promoting health care including preventive healthcare, sanitation & providing safe drinking water*
- *Providing mobile toilets to prevent open defecation*
- *Construction of home for old aged people and orphans*
- *Income enhancement through farm based and other livelihood opportunities*
- *Promoting/supporting any activities covered under Schedule VII of the Companies Act, 2013.*

The Board had approved the CSR policy of the Company. It can be viewed at the company website [www.samratpharmachem.com](http://www.samratpharmachem.com)

## 2. Composition of the CSR Committee:

Sr. No.	Name	Designation / Name of Directorship	Number of meetings of CSR Committee held during the year	Number of Meetings of CSR Committee attended during the year
1.	Ms. Renu Dharod	Chairperson Non-Executive, Independent Director	2	2
2.	Mr. Lalit Mehta	Member Executive Director	2	2
3.	Mr. Rajesh Mehta	Member Executive Director	2	2
4.	Mr. Megh Mehta	Member Executive Director	2	2
5.	Mr. Mahendra Pipalia	Member Non-Executive, Independent Director	2	2
6.	Mr. Samir Kothary	Member Non-Executive, Independent Director	2	2

## 3. Provide the web-link where Composition of CSR committee, CSR Policy approved by the board are disclosed on the website of the Company

Composition of the CSR committee shared above and is available on the Company's website on <https://www.samratpharmachem.com/investors/investor-service/>

CSR Policy - <https://www.samratpharmachem.com/corporate-social-policy/>

## 4. Provide the details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014, if applicable (attach the report).

Not applicable

## 5. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social Responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any

Sr. No.	Financial Year	Amount available for set-off from preceding financial years (in Rs.)	Amount required to be set-off from preceding financial years (in Rs.)
1	-	-	Nil

## 6. Average net profit of the company for last three financial years : Rs. 4,28,76,789

Particulars	F.Y. 2017-18 (31-03-18)	F.Y. 2018-19 (31-03-19)	F.Y. 2019-20 (31-03-20)
Profit Before Tax	49,203,221	21,577,256	57,849,890

Total Profit Before Tax of 3 Years 128,630,367

Average Net Profit of 3 Years 42,876,789

7. a 2% of Average Net Profit for the purpose of CSR Expenditure of the Company as per Section 135(5) : ₹ 857,536
- b Surplus arising out of the CSR projects or programmes or activities of the previous financial years : Nil
- c Amount required to be set off for the financial year, if any : Nil
- d Total CSR obligation for the financial year (7a+7b-7c) : ₹ 857,536

## 8. a Details of CSR spent or unspent during the financial year

Total Amount Spent for the Financial Year	Amount unspent				
	Total Amount transferred to Unspent CSR Account as per Section 135(6)		Amount transferred to any fund specified under Schedule VII as per second proviso to Section 135(5)		
	Amount	Date of Transfer	Name of the Fund	Amount	Date of Transfer
₹ 840,883	₹ 16,653	31/03/2021	-	-	-

## b Details of CSR amount spent against ongoing projects for the financial year:

Sr. No.	Name of the Project	Item from the list of activities in schedule VII to the Act	Local Area (Yes / No)	Location	Amount spent	Mode of implementation - Direct (Yes / No)	Mode of implementation - Through implementing agency Name / CSR registration no.
1	-	-	-	-	Nil	-	-



## c Details of CSR amount spent against other than ongoing projects for the financial year:

Sr. No.	Name of the Project	Item from the list of activities in schedule VII to the Act	Local Area (Yes / No)	Location	Amount spent	Mode of implementation - Direct (Yes / No)	Mode of implementation - Through implementing agency
							Name / CSR registration no.
1	Education	ii	No	Mumbai, Maharashtra	₹ 668,083	Yes	Shree Pandit Ratanchandraji Jain Kanyashala Trust CSR00005094
2	Education	ii	No	Mumbai, Maharashtra	₹ 172,800	Yes	Smt. Kumudben Dwarkadas Vora Industrial Home for Blind Women CSR00011329
Total					₹ 840,883		

- b Amount spent in Administrative Overheads : Nil
- c Amount spent on Impact Assessment, if applicable : Nil
- d Total amount spent for the Financial Year (8a+8b+8c) : ₹ 840,883
- e Excess amount for set off, if any : ₹ 0.00

Sr. No.	Particulars	Amount (Rs.)
1.	Two percent of average net profit of the Company as per Section 135(5)	857,536
2.	Total amount spent for the financial year	840,883
3.	Excess amount spent for the financial year	Nil
4.	Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	Nil
5.	Amount available for set off in succeeding financial years	Nil

## 9. a Details of Unspent CSR amount for the preceding three financial years:

Sr. No.	Preceding Financial year	Amount transferred to Unspent CSR Account under Section 135 (6) (Rs.)	Amount spent in the reporting Financial Year (Rs.)	Amount transferred to any fund specified under Schedule VII as per Section 135(6), if any			Amount remaining to be spent in succeeding financial years (Rs.)
				Name of the fund	Amount (Rs.)	Date of transfer	
1	-	Nil	Nil	-	Nil	-	-

- b Details of CSR amount spent in the financial year for ongoing projects of the preceding financial year(s):

Sr. No.	Project ID	Name of the Project	Financial Year in which the project was commenced	Project Duration	Total amount allocated for the project	Amount spent on the project in the reporting Financial Year	Cumulative amount spent at the end of reporting Financial Year	Status of the project - Completed / Ongoing
1	-	-	-	-	Nil	Nil	Nil	NA

10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year (asset-wise details)

- Date of creation or acquisition of the capital asset(s)  
Nil
- Amount of CSR spent for creation or acquisition of capital asset:  
Nil
- Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc.  
Not applicable
- Provide details of the capital asset(s) created or acquired (including complete address and location of the capital asset)  
Not applicable

11. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per section 135(5).

CSR Projects were identified but not executed within the stipulated time.

By order of the Board of Directors  
For Samrat Pharmachem Limited

Lalit Mehta  
Chairman & Managing Director  
DIN : 00216681

Renu Dharod  
Chairperson CSR Committee  
DIN: 07063088

## Annexure II to the Directors Report

### REMUNERATION RATIO OF THE DIRECTORS / KEY MANAGERIAL PERSONNEL (KMP) / EMPLOYEES

Statement of Disclosure of Remuneration under Section 197 of the Companies Act, 2013 and Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

- i. Ratio of the remuneration of each Executive Director to the median remuneration of the Employees of the Company for the financial year 2020-21, the percentage increase in remuneration of Chief Executive Officer, Chief Financial Officer and other Executive Director(s) and Company Secretary during the financial year 2020-21.

Sr. No.	Name of the Director(s) / KMP	Designation	Ratio of remuneration of each Director to median remuneration of Employees
1	Lalit Mehta	Chairman & Managing Director	8.82
2	Rajesh Mehta	Executive Director	8.53
3	Megh Mehta	Executive Director	4.41
4	Nishant Kankaria	Company Secretary	0.82

- ii. The Company has 27 permanent Employees on the rolls of Company as on 31st March, 2021.
- iii. It is hereby affirmed that the remuneration paid during the year is as per the Remuneration Policy of the Company.
- a) The Non-Executive Directors of the Company are entitled to sitting fee as per the statutory provisions and within the limits approved by the Members. The remuneration of Non-Executive Directors, details of which are provided in the Corporate Governance Report and is governed by the Differential Remuneration Policy, as detailed in the said Report. The ratio of remuneration and percentage increase for Non-Executive Directors Remuneration is therefore not considered for the purpose above.
- b) Percentage increase in remuneration indicates annual target total compensation increases, as approved by the Nomination and Remuneration Committee of the Company during the financial year 2020-21.

**By order of the Board of Directors  
For Samrat Pharmachem Limited**

**Lalit Mehta**  
**Chairman & Managing Director**  
**DIN : 00216681**

**Annexure III to the Directors Report****Form MR-3****Secretarial Audit Report**

For The Financial Year Ended March 31, 2021

[Pursuant to section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,

**The Members,**

**Samrat Pharmachem Limited**

**[CIN: L24230GJ1992PLC017820]**

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **M/s. Samrat Pharmachem Limited** (hereinafter called “the Company”). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of Samrat Pharmachem Limited's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, the explanation and clarifications given to me, the representations made by the Management and considering the relaxations granted by the Ministry of Corporate Affairs and Securities and Exchange Board of India warranted due to the spread of the COVID-19 pandemic. I hereby report that in my opinion, the Company has, during the financial year commencing from 1st April, 2020 and ending on 31st March, 2021, complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records made available to me and maintained by M/s. Samrat Pharmachem Limited for the financial year ended on 31st March, 2021, according to the applicable provisions of:

- i. The Companies Act, 2013 (the Act) and the rules made thereunder, as applicable;
- ii. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- iii. The Depositories Act, 1996 and the rules made thereunder;
- iv. Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- v. The following Regulations and Guidelines prescribed under The Securities and Exchange Board of India Act, 1992 ('SEBI Act') :
  - a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and takeovers) Regulation, 2011;
  - b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
  - c. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulation 2018;  
**Not applicable to the company during the audit period**

- d. The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014;  
**Not applicable to the company during the audit period**
  - e. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008;  
**Not applicable to the company during the audit period**
  - f. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client.  
**Not applicable to the company during the audit period**
  - g. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009:  
**Not applicable to the company during the audit period**
  - h. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018;  
**Not applicable to the company during the audit period**
- vi. Other laws applicable to the Company are as under :
- i. The Factories Act, 1948
  - ii. Environment Protection Act, 1986
  - iii. The Environmental Impact Assessment Notification, 2006
  - iv. Water (Prevention & Control of Pollution) Act 1974 and rules there under
  - v. Air (Prevention & Control of Pollution) Act 1981 and rules there under
  - vi. Hazardous Wastes (Management & Handling) Rules 1989 and Amendment Rules, 2003
  - vii. The Child Labour (Prohibition & Regulation) Act, 1986
  - viii. The Industrial Employment (Standing Order) Act, 1946
  - ix. The Inflammable Substances Act, 1952
  - x. The Legal Metrology Act, 2009 and Legal Metrology (Packaged Commodities) Rules, 2011
  - xi. The Petroleum Act, 2002
  - xii. The Poisons Act, 1919
  - xiii. The Indian Boiler Act, 1923
  - xiv. Manufacture, storage and Import of Hazardous Chemicals Rules, 1989
  - xv. The Payment of Wages Act, 1936
  - xvi. The Public Liability Insurance Act, 1991
  - xvii. Employees Provident Fund and Miscellaneous Provisions Act, 1952
  - xviii. The Energy Conservation Act, 2001
  - xix. Food Safety & Standard Act 2006 & Food Safety And Standards Rules, 2011
- vii. Due to prevailing circumstance of COVID-19 pandemic, the audit was conducted based on the verification of the Company's books, papers, minutes books, forms and returns filed, documents and other records furnished by / obtained from the Company electronically and also the information provided by the Company and its officers by audio and visual means.

I have also examined compliance with the applicable clauses of the following:

- i. Secretarial Standards issued by the Institute of Company Secretaries of India with respect to Board and general meetings.
- ii. The Listing Agreement entered into by the Company with BSE Limited read with the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

**During the period under review, the Company has complied with the provisions of the Acts, Rules, Regulations, Guidelines, Standards etc. as mentioned above except:**

- i. The company has been issued show cause notice by BSE Limited for violation of following regulation under SEBI (LODR) Regulation, 2015 during the year under review

- a. **Regulation 31:  
Submission of Shareholding Pattern for the quarter ended 31st March, 2020**

The Company had delayed submission of the shareholding pattern of the quarter ended 31st March, 2020 to the stock exchange as against the requirements of submission within 21 days of the close of the quarter.

BSE Limited imposed penalty of Rs. 23,600/- for delay in submission of Shareholding Pattern for the quarter ended March, 2020 vide email dated 02-June-2020

The Company had submitted shareholding pattern for the quarter ended 31st March, 2020 on 27-May-2020 late by 15 days with the stock exchange thereby violating the provision of Regulation 31 of the SEBI (LODR), Regulation, 2015. Considering the relaxation of 3 weeks given by SEBI due to the Covid-19 virus pandemic vide PR No. 17/2020 Dated 19 March, 2020, the delay of 15 days occurred.

The Company has paid the penalty imposed by BSE on 25-March-2021.

- b. **Regulation 13(3):  
Submission of Statement of Investors Complaints for the quarter ended 31st March, 2020**

The Company had delayed submission of the Statement of Investors complaints of the quarter ended 31st March, 2020 to the stock exchange as against the requirements of submission within 21 days of the close of the quarter.

BSE Limited imposed penalty of Rs.14,160/- on the listed entity for delay in submission of statement of investor complaints for the quarter ended 31st March, 2020 vide email dated 03-June-2020

The Company had submitted statement of investor complaints for the quarter ended 31st March, 2020 on 29-May-2020 late by 17 days with the stock exchange thereby violating the provision of Regulation 13(3) of the SEBI (LODR), Regulation, 2015 Considering the relaxation of 3 weeks given by SEBI due to the Covid-19 virus pandemic vide PR No. 17/2020 Dated 19 March, 2020, the delay of 17 days occurred.

The Company has paid the penalty imposed by BSE on 25-March-2021.

c. **Regulation 27(2):****Submission of the Corporate Governance Report for the quarter ended 31st March, 2020**

The Company had delayed submission of the Corporate Governance Report of the quarter ended 31st March, 2020 to the stock exchange as against the requirements of submission within 15 days of the close of the quarter.

BSE Limited imposed penalty of Rs.28,320/ on listed entity for delay in submission of Corporate Governance Report for the quarter ended 31st March, 2020 vide email dated 04-Sep-2020.

The Company had submitted the Corporate Governance Report for March 2020 on 29-May-2020 late by 14 days with the stock exchange thereby violating the provision of Regulation 13(3) of the SEBI (LODR), Regulation, 2015 for the quarter ended 31st March, 2020. Considering the relaxation of 1 month given by SEBI due to the Covid-19 virus pandemic vide PR No. 17/2020 Dated 19 March, 2020, the delay of 14 days occurred.

The Company has paid the penalty imposed by BSE on 25-March-2021.

d. **Regulation 31:****Submission of Shareholding Pattern for the quarter ended 30th September, 2020**

The Company had delayed submission of the Shareholding Pattern of the quarter ended 30th September, 2020 to the stock exchange as against the requirements of submission within 21 days of the close of the quarter.

BSE Limited imposed penalty of Rs. 14,160/- for delay in submission of Shareholding Pattern of the quarter ended 30th September, 2020 vide email dated 15-Dec-2020.

The listed entity had submitted Shareholding Pattern on 27-Oct-2020 for the quarter ended 30th September, 2020 late by 6 days with the stock exchange thereby violating the provision of Regulation 31 of the SEBI (LODR), Regulation, 2015.

The Company has paid the penalty imposed by BSE on 25-March-2021.

I further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors and Non-executive Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice was given to all Directors at least seven days in advance to schedule the Board Meetings. Agenda and detailed notes on agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

Decisions at the Board Meetings, as represented by the management, were taken unanimously.

I further report that as per the explanations given to me and the representations made by the Management and relied upon by me there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

**Place : Mumbai**  
**Date : 30 June 2021**

**For A.A. Mulla & Associates**  
**Company Secretaries**

**Aqueel A. Mulla**  
**Proprietor**  
**FCS NO. 2973**  
**C.P. No.3237**  
**UDIN: F002973C000547220**

\* This report should be read with my letter of even date which is annexed as Annexure A and forms an integral part of this report.



**'Annexure A'**

To,  
**The Members,**  
**Samrat Pharmachem Limited**  
**[CIN: L24230GJ1992PLC017820]**

My report of even date is to be read along with this letter.

- 1 Maintenance of Secretarial record is the responsibility of the management of the Company. My responsibility is to express an opinion on these secretarial records based on my audit.
- 2 I have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in Secretarial records. I believe that the process and practices I followed provide a reasonable basis for my opinion.
- 3 I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
- 4 Where ever required, I have obtained the Management representation about the Compliance of laws, rules and regulations and happening of events etc.
- 5 The Compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. My examination was limited to the verification of procedure on test basis.
- 6 The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.
- 7 Due to the pandemic caused by Covid-19 and prevailing lockdowns/restrictions on movement of people imposed by the Government, for the purpose of issuing this report, we have conducted our audit remotely based on the records and information made available to me by the Company electronically.

**Place : Mumbai**  
**Date : 30 June 2021**

**For A.A. Mulla & Associates**  
**Company Secretaries**

**Aqueel A. Mulla**  
**Proprietor**  
**FCS NO. 2973**  
**C.P. No.3237**  
**UDIN: F002973C000547220**

## **CORPORATE GOVERNANCE REPORT**

We at Samrat Pharmachem believe that for a Company to succeed it must maintain global standards of Corporate Conduct towards its customers, suppliers, employees, bankers, shareholders and the society at large. The Company believes that it is rewarding to be better managed and governed and to identify and align its activities with national interest. To that end we as a Company have always focused on Good Corporate Governance - which is a key driver of sustainable corporate growth and long term value & wealth creation.

Above all else, Corporate Governance must balance individual interest with Corporate Goals and operate within accepted norms of propriety, equity, fair play and a sense of justice. Achieving this balance depends upon how accountable and transparent companies are. Accountability improves decision-making and thereby builds stakeholders confidence.

Corporate Governance is not merely compliance - it is an ongoing measure of superior delivery of company's objects with a view to translate opportunities into reality. It involves leveraging its resources and aligning its activities to consumer need, shareholders benefit and employee growth, thereby delighting all its stakeholders while minimizing risks.

The Company has a good corporate practice complies with the requirements stipulated under regulation 17 to 27 read with Schedule V and clauses (b) to (i) of sub-regulation (2) of regulation 46 of SEBI Listing Regulations, with regard to corporate governance.

### **COMPANY'S PHILOSOPHY**

Samrat Pharmachem Limited is committed to the best practices in the area of Corporate Governance. The company believes that proper corporate governance facilitates effective management and control of business. This in turn, enables the company to maintain a high level of business ethics and to optimize the value of all its stakeholders. The objectives can be summarized as under:

- To enhance shareholders value.
- To protect interest of shareholders and other stakeholders including customers, suppliers, banks, employees and society at large.
- To ensure transparency and integrity in communication and to make available full, accurate and clear information to all concerned.
- To ensure accountability for performance and to achieve excellence at all levels.
- To provide corporate leadership of highest standards for other to follow.

Samrat Pharmachem Limited is committed to:

- Ensuring that the Board of Directors of the Company meet regularly, provide effective leadership, exercise control over management and monitor executive performance.
- Establishing a framework of strategic control and continuously reviewing its efficacy.
- Establishing clearly documented and transparent management processes for policy development, implementation and review, decision-making, monitoring, control and reporting.
- Providing free access to the Board to all relevant information, advices and resources as are necessary to enable it to carry out its role effectively.
- Ensuring that all employees are responsible for compliance issues with all applicable statutes, regulations, code of conduct, policies as laid down by the Board and report deviation or misconduct, if any, to the Board.

The concept of Corporate Governance hinges on the total transparency, integrity and accountability of the management team. Even before the code become mandatory, the Company has been following the Corporate Governance practices like striking out reasonable balance in the composition of Board of Directors and setting up business committees, adequate disclosure and business to be deliberated by the Board etc. Your Company is committed to follow good corporate governance practices and improve upon them year after year.

## II. BOARD OF DIRECTORS

i. *Composition of the Board*

The composition of the board is in conformity with Regulation 17 of the SEBI Listing Regulations read with Section 149 of the Act. As of March 31, 2021, the Company has 6 directors. Of the 6 Directors, 3 (i.e. 50%) are Executive Directors and 3 (i.e. 50%) are Non-executive Independent Directors. The profiles of the Directors are available at <https://www.samratpharmachem.com/about-us/management-team/>

ii. *Independent Directors*

Independent directors are Non-executive Directors as defined under Regulation 16(1)(b) of the SEBI Listing Regulations read with Section 149(6) of the Act. The maximum tenure of the independent directors is in compliance with the Companies Act, 2013 ("Act"). All the Independent Directors have confirmed that they meet the criteria as mentioned under Regulation 16(1)(b) of the SEBI Listing Regulations read with Section 149(6) of the Act. Further, the Independent Directors have included their names in the data bank of Independent Directors maintained with the Indian Institute of Corporate Affairs in terms of Section 150 of the Act read with Rule 6 of the Companies (Appointment & Qualification of Directors) Rules, 2014.

iii. *Directors' attendance record and Directorship held*

The names and categories of the directors on the board, their attendance at board meetings held during the year and the number of directorships and committee chairmanships / memberships held by them in other public companies as on March 31, 2021 are given herein below. Other directorships do not include directorships of private limited companies, Section 8 companies and of companies incorporated outside India. Chairmanships / memberships of board committees shall include only audit committee and stakeholders' relationship committee.

Name of the Director	Category	Number of Board meetings during the year 2020-21		Whether attended last AGM held on December 31, 2020	Number of directorships in other Public Companies		Number of committee positions held in other Public Companies	
		Held	Attended		Chairman	Member	Chairman	Member
Mr. Lalit Mehta (Chairperson & MD) DIN 00216681	Non-Independent, Executive	6	6	Yes	-	-	-	-
Mr. Rajesh Mehta (CFO) DIN 00216731	Non-Independent, Executive	6	6	Yes	-	-	-	-
Mr. Megh Mehta DIN 07287394	Non-Independent, Executive	6	6	Yes	-	-	-	-
Mr. Mahendra Pipalia DIN 00216959	Independent, Non-Executive	6	6	Yes	-	-	-	-
Mr. Samir Kothary DIN 00216603	Independent, Non-Executive	6	6	Yes	-	-	-	-
Ms. Renu Dharod DIN 00216731	Independent, Non-Executive	6	6	Yes	-	-	-	-

None of the Directors is a member of more than 10 Board-level Committees or a Chairman of more than 5 such committees, as required under SEBI (Listing Obligations & Disclosures Requirements) Regulation, 2015.

iv. *Number of Board Meetings*

6 Board Meetings were held during the year and the maximum interval between 2 Board Meetings was not more than 4 calendar months. The dates on which the said meetings were held is as under :-

Sr No	Date of Board Meeting
1	25th June, 2020
2	31st July, 2020
3	14th September, 2020
4	13th November, 2020
5	13th February, 2021
6	31st March, 2021

The necessary quorum was present for all the meetings.

v. *Selection of Independent Directors*

The company has constituted Nomination and Remuneration Committee for appointment of independent directors on the Board of the company. The committee inter alia considers qualification, positive attributes, area of expertise and no. of directorship and membership held in various committees of other companies.

The Board considers the committee's recommendation and take appropriate decision. Every independent Director at the first meeting of Board in which he / she participates as a Director and thereafter at every first meeting of the Board in every financial year gives a declaration that he meets with the criteria of independence as provided under law.

vi. *Independent Directors Meeting*

During the year a separate meeting of the independent directors was held inter-alia to review the performance of non-independent directors and the board as a whole.

vii. *Directors Induction and Familiarization program*

The Program aims to provide insights into the Company to enable the Independent Directors to understand its business in depth and contribute significantly to the Company. The provision of an appropriate induction program for new Directors and ongoing training for existing directors is a major contributor to the maintenance of high Corporate Governance standards of the Company.

The Independent Directors, from time to time request management to provide detailed understanding of any specific project, activity or process of the Company. The management provides such information and training either at the meeting of Board of Directors or otherwise. The induction process is designed to:

- a. Familiarize with the nature of Business of the Company.
- b. Roles and Responsibilities.
- c. Nature of industry including competition/export potential.
- d. The business model and Corporate Plans [Long Term and Short Term] of the Company

viii. *Code of Conduct*

The company has in place a comprehensive Code of Conduct applicable to all the employees and on Executive Directors including Independent Directors. The code is applicable to Non- Executive Directors including Independent Directors to such an extent as may be applicable to them depending on their roles and responsibilities. The code gives guidance and support needed for ethical conduct of business and compliance of law. A copy of the Code has been posted on the website of the company [www.samratpharmachem.com](http://www.samratpharmachem.com). The code is circulated to the Directors and management personnel and its compliance is affirmed by them annually.

ix. *Details of equity shares of the Company held by the Directors as on March 31, 2021 are given below:*

Name	Category	Number of equity shares
Mr. Lalit Mehta	Non-Independent, Executive	431,498
Mr. Rajesh Mehta	Non-Independent, Executive	381,042
Mr. Megh Mehta	Non-Independent, Executive	43,900

**III. COMMITTEES OF THE BOARD****A Audit Committee**

- i. The audit committee of the Company is constituted in line with the provisions of Regulation 18 of SEBI Listing Regulations, read with Section 177 of the Act.
- ii. The audit committee performs the following functions:
  - Overseeing the company's financial reporting process and disclosure of financial information to ensure that the financial statement is correct, sufficient and credible;
  - Recommending the appointment of auditors of the Company, terms of appointment, fixation of audit fee and approval for payment of any other services;
  - Reviewing with the management, the annual financial statements and auditors' report thereon before submission to the board for approval, with particular reference to:
    - ⇒ Matters required to be included in the directors' responsibility statement to be included in the board's report in terms of clause (c) of sub-section 3 of section 134 of the Act
    - ⇒ Changes, if any, in accounting policies and practices and reasons for the same
    - ⇒ Major accounting entries involving estimates based on the exercise of judgment by management
    - ⇒ Significant adjustments made in the financial statements arising out of audit findings
    - ⇒ Compliance with listing and other legal requirements relating to financial statements
    - ⇒ Disclosure of any related party transactions
    - ⇒ Qualifications in the draft audit report
  - Reviewing with the management, the quarterly financial statements before submission to the board for approval;
  - Reviewing with the management and external and internal auditors, the adequacy of internal control system;
  - Reviewing the adequacy of internal audit system;
  - Discussing with internal auditors any significant finding and follow up on such issues;
  - Reviewing the findings of any internal investigation by internal auditors in matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and then reporting such matter to the Board;
  - Discussing with the statutory auditors before the audit commences on the nature and scope of audit as well as having post-audit discussion to ascertain any area of concerns;
  - Examining reasons for substantial default in the payment to depositors, bankers, shareholders (in case of non-payment of declared dividends) and creditors, if any;
  - Reviewing compliance with the provision of regulation 9(1) & (2) of the SEBI Insider Trading Regulation 2015 - Internal control atleast once in a financial year
  - Establish a vigil mechanism for directors and employees to report genuine concerns in such manner as may be prescribed;
  - To review the functioning of whistle blower mechanism
  - The audit committee may call for the comments of the auditors about internal control systems, the scope of audit, including the observations of the auditors and review of financial statement before their submission to the board and may also discuss any related issues with the internal and statutory auditors and the management of the Company;

- Carrying out any other function as is mentioned in the terms of reference of the audit committee;
  - To mandatorily review the following information:
    - ⇒ Management discussion and analysis of financial condition and results of operations;
    - ⇒ Statement of significant related party transactions (as defined by the audit committee), submitted by management;
    - ⇒ Management letters / letters of internal control weaknesses issued by the statutory auditors;
    - ⇒ Internal audit reports relating to internal control weaknesses; and
    - ⇒ The appointment, removal and terms of remuneration of the chief internal auditor.
- iii. The previous annual general meeting (AGM) of the Company was held on December 31, 2020 and was attended by Mr. Mahendra Pipalia, Chairman of the audit committee.
- iv. Composition of Audit Committee and details of meetings attended:

Name	Category	Number of meetings during the financial year 2020-21	
		Held	Attended
Mr. Mahendra Pipalia (Chairman)	Independent, Non-Executive	5	5
Mr. Samir Kothary (Member)	Independent, Non-Executive	5	5
Ms. Renu Dharod (Member)	Independent, Non-Executive	5	5

- v. 5 audit committee meetings were held during the year and the gap between two meetings did not exceed 4 months. The dates on which the said meetings were held are as follows:  
June 25, 2020; July 31, 2020; September 14, 2020; November 13, 2020 and February 13, 2021  
The necessary quorum was present for all the meetings.

## B Nomination and Remuneration Committee

- i. The nomination and remuneration committee of the Company is constituted in line with the provisions of Regulation 19 of SEBI Listing Regulations, read with Section 178 of the Act.
- ii. The nomination and remuneration committee performs the following functions:
- Recommend to the board the appointment or reappointment of directors.
  - Devise a policy on board diversity.
  - Carry out evaluation of every director's performance and support the board and independent directors in evaluation of the performance of the board, its committees and individual directors. This shall include "formulation of criteria for evaluation of independent directors and the board".
  - Recommend to the board the remuneration policy for directors, executive team or key managerial personnel as well as the rest of the employees.
  - On an annual basis, recommend to the board the remuneration payable to the directors and oversee the remuneration to executive team or key managerial personnel of the Company.
  - Oversee familiarisation programmes for directors.

- Performing such other duties and responsibilities as may be consistent with the provisions of the committee charter.

iii. Composition of Nomination and Remuneration Committee and details of meetings attended:

Name	Category	Number of meetings during the financial year 2020-21	
		Held	Attended
Mr. Samir Kothary (Chairman)	Independent, Non-Executive	5	5
Mr. Mahendra Pipalia (Member)	Independent, Non-Executive	5	5
Ms. Renu Dharod (Member)	Independent, Non-Executive	5	5

iv. During the year 5 meetings of the nomination and remuneration committee were held. The dates on which the said meetings were held are as follows:

June 25, 2020; July 31, 2020; September 14, 2020; November 13, 2020 and February 13, 2021

v. The Company does not have any employee stock option scheme.

vi. **Remuneration to Directors: sitting fees, salary, perquisites and commissions**

a. **Executive Directors**

((₹)  
lakh)

Name	Salary	Perquisites
Mr. Lalit Mehta	18.00	-
Mr. Rajesh Mehta	17.40	-
Mr. Megh Mehta	9.00	-
<b>Total</b>	<b>44.40</b>	-

b. **Independent Non-Executive Directors**

((₹)  
lakh)

Name	Commission	Sitting Fees
Mr. Mahendra Pipalia	-	1.00
Mr. Samir Kothary	-	1.00
Ms. Renu Dharod	-	1.00
<b>Total</b>	-	<b>3.00</b>



**C Stakeholders' relationship committee**

- i. The Company had a shareholders / investors grievance committee of directors to look into the redressal of complaints of investors such as transfer or credit of shares, non-receipt of dividend / notices / annual reports, etc.
- ii. Composition of Stakeholders' Relationship Committee and details of meetings attended:

Name	Category	Number of meetings during the financial year 2020-21	
		Held	Attended
Ms. Renu Dharod (Chairperson)	Independent, Non-Executive	5	5
Mr. Samir Kothary (Member)	Independent, Non-Executive	5	5
Ms. Mahendra Pipalia (Member)	Independent, Non-Executive	5	5

- iii. During the year 5 meetings of the Stakeholders' relationship committee were held. The dates on which the said meetings were held are as follows:  
June 25, 2020; July 31, 2020; September 14, 2020; November 13, 2020 and February 13, 2021
- iv. Mr. Nishant Kankaria acts as compliance officer of the company.
- v. Investor complaints received and redressed during the year 2020-21

Opening balance	Received during the year	Resolved during the year	Closing balance
0	0	0	0

**D Risk Management Committee**

The board of the Company has formed a risk management committee to frame, implement and monitor the risk management plan for the Company. The committee is responsible for reviewing the risk management plan and ensuring its effectiveness. Major risks identified by the businesses and functions are systematically addressed through mitigating actions on a continuing basis.

Composition of Risk Management Committee and details of meetings attended:

Name	Category	Number of meetings during the financial year 2020-21	
		Held	Attended
Ms. Renu Dharod (Chairperson)	Independent, Non-Executive	5	5
Mr. Samir Kothary (Member)	Independent, Non-Executive	5	5
Mr. Mahendra Pipalia (Member)	Independent, Non-Executive	5	5

During the year 5 meetings of the Risk management committee were held. The dates on which the said meetings were held are as follows:

June 25, 2020; July 31, 2020; September 14, 2020; November 13, 2020 and February 13, 2021

**E Health, Safety and Sustainability Committee**

The Health, safety and sustainability committee of directors is responsible for framing and implementation of broad guidelines / policies with regard to the health, safety and sustainability activities of the Company review the policies, processes and systems periodically and recommend measures for improvements from time to time.

Composition of Health, Safety and Sustainability Committee and details of meetings attended:

Name	Category	Number of meetings during the financial year 2020-21	
		Held	Attended
Mr. Samir Kothary (Chairman)	Independent, Non-Executive	5	5
Mr. Mahendra Pipalia (Member)	Independent, Non-Executive	5	5
Ms. Renu Dharod (Member)	Independent, Non-Executive	5	5

During the year 5 meetings of the Health, Safety and Sustainability Committee were held. The dates on which the said meetings were held are as follows:

June 25, 2020; July 31, 2020; September 14, 2020; November 13, 2020 and February 13, 2021

**F CSR Committee**

The CSR Committee is constituted in line with the provisions of Section 135 of the Companies Act, 2013 and rules made thereunder.

Term of reference

The committee recommends to the Board, the amount of expenditure to be incurred on CSR activities. The committee frames the transparent monitoring mechanism for implementation of CSR Project / Program / Activities to be undertaken by the Company as required under Schedule VII of the Companies Act and for monitoring the CSR policies from time to time.

Composition of CSR Committee and details of meetings attended:

Name	Category	Number of meetings during the financial year 2020-21	
		Held	Attended
Ms. Renu Dharod (Chairman)	Independent, Non-Executive	2	2
Mr. Mahendra Pipalia (Member)	Independent, Non-Executive	2	2
Mr. Samir Kothary (Member)	Independent, Non-Executive	2	2
Mr. Lalit Mehta (Member)	Chairperson & MD	2	2
Mr. Rajesh Mehta (Member)	Executive Director	2	2
Mr. Megh Mehta (Member)	Executive Director	2	2

During the year 2 meetings of the Corporate Social Responsibility Committee were held. The dates on which the said meetings were held are as follows:

November 13, 2020 and February 13, 2021

**IV. GENERAL BODY MEETINGS****i. General meeting****a. Annual General Meeting:**

Details of the last three Annual General Meetings (AGMs) along with special resolutions passed:

Financial Year	Date	Time	Venue	Special Resolutions Passed	
2017-18	22/Sep/2018	1.00 p.m.	Plot No. A2/3445, GIDC, Phase 4, Ankleshwar - 393 002, Gujarat.	No Special Resolutions were passed during the year	
2018-19	28/Sep/2019	1.00 p.m.	Plot No. A2/3445, GIDC, Phase 4, Ankleshwar - 393 002, Gujarat.	1	Re-appointment of Mr. Mahendra Indulal Pipalia (DIN: 00216959), as an Independent Director of the Company
				2	Re-appointment of Mr. Samir Harsukhrai Kothary (DIN: 00216603), as an Independent Director of the Company
2019-20	31/Dec/2020	1.00 p.m.	VC / OAVM	1	Re-appointment of Mr. Lalit Damodar Mehta as Chairman & Managing Director of the Company
				2	Re-appointment of Mr. Rajesh Lalit Mehta as an Executive Director of the Company
				3	Re-appointment of Mr. Megh Rajesh Mehta as an Executive Director of the Company
				4	Re-appointment of Ms. Renu Piyush Dharod as an Independent Director of the Company

**b. Extraordinary general Meeting:**

No extraordinary general meeting of the members was held during the year 2020-21.

**ii. Postal Ballot**

Details of special resolution passed through postal ballot, the persons who conducted the postal ballot exercise and details of the voting pattern

During the year under review, no special resolution has been passed through the exercise of postal ballot.

Details of special resolution proposed to be conducted through postal ballot:

Nil

**V. DISCLOSURES****i. Related Party transactions**

As required under Regulation 23 of SEBI Listing Regulations and as defined under the Act, the company has not entered into any transaction of a material nature with the Promoters, Directors or the Management, their relatives etc. that may have any potential conflict with the interests of the company. The Board has approved a policy for related party transactions which has been uploaded on the Company's website at the following link-

<http://www.samratpharmachem.com/policy-on-related-party-transactions-and-its-materiality/>

**ii. Stock Exchange/ SEBI Compliances**

As per Schedule V (C) 10(b) to the SEBI Listing Regulations, the company has complied with the requirements of the stock exchanges, SEBI and other statutory authorities on all matters related to capital markets during the last three years. However, few penalties were imposed on the Company by the Stock Exchanges, SEBI or any other statutory authority relating to small non compliances, details of which are listed below.

- The Company had delayed submission of the shareholding pattern of the quarter ended 31st March, 2020 to the stock exchange as against the requirements of submission within 21 days of the close of the quarter. BSE Limited imposed penalty of Rs. 23,600/- for delay in submission of Shareholding Pattern for the quarter ended March, 2020 vide email dated 02-June-2020. The Company has paid the penalty imposed by BSE on 25-March-2021.
- The Company had delayed submission of the Statement of Investors complaints of the quarter ended 31st March, 2020 to the stock exchange as against the requirements of submission within 21 days of the close of the quarter. BSE Limited imposed penalty of Rs.14,160/- on the listed entity for delay in submission of statement of investor complaints for the quarter ended 31st March, 2020 vide email dated 03-June-2020. The Company has paid the penalty imposed by BSE on 25-March-2021.
- The Company had delayed submission of the Corporate Governance Report of the quarter ended 31st March, 2020 to the stock exchange as against the requirements of submission within 15 days of the close of the quarter. BSE Limited imposed penalty of Rs.28,320/ on listed entity for delay in submission of Corporate Governance Report for the quarter ended 31st March, 2020 vide email dated 04-Sep-2020. The Company has paid the penalty imposed by BSE on 25-March-2021.
- The Company had delayed submission of the Shareholding Pattern of the quarter ended 30th September, 2020 to the stock exchange as against the requirements of submission within 21 days of the close of the quarter. BSE Limited imposed penalty of Rs. 14,160/- for delay in submission of Shareholding Pattern of the quarter ended 30th September, 2020 vide email dated 15-Dec-2020. The Company has paid the penalty imposed by BSE on 25-March-2021.

**iii. Whistle Blower Policy**

The Company has adopted a whistle blower policy and has established the necessary vigil mechanism as defined under Regulation 22 of SEBI Listing Regulations for employees and directors to report concerns about unethical behaviour. No person has been denied access to the chairman of the audit committee. The said policy has been also put on the website of the company at the following link-

<http://www.samratpharmachem.com/whistleblower-policy/>

- iv. **Materiality of Events Policy**  
The Company has also adopted Policy on Determination of Materiality of Events as required under Regulation 30 of SEBI Listing Regulations  
<http://www.samratpharmachem.com/policies/materiality-of-events-policy/>
- v. **Archival Policy**  
The Company has adopted Policy for archival of documents as required under Regulation 9 of SEBI Listing Regulations.  
<http://www.samratpharmachem.com/archival-policy/>
- vi. **Code Of Conduct For Prevention Of Insider Trading**  
The Company has adopted revised Code of Conduct pursuant to the provisions of the SEBI (Prohibition of Insider Trading] Regulations, 2015, for prevention of insider trading in the shares of the Company. The comprehensive Code has been disseminated on the intranet and strictly implemented aiming at maintaining the highest ethical standards. The Code which is applicable to promoters, directors, auditors, employees of the Company and their immediate relatives, prescribes the procedures to be followed while dealing in the shares of the Company. The Code prohibits the said persons to deal in the shares of the Company on the basis of any unpublished price sensitive information available to them by virtue of their position in the Company. The transactions in the shares of the Company are also subjected to the trading window closure periods announced by the Company, from time to time.
- vii. **Reconciliation of share capital audit**  
As defined under Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 and SEBI Circular No D&CC / FITTC/ Cir-16/2002 dated December 31, 2002, a qualified practicing Company Secretary carried out a share capital audit to reconcile the total admitted equity share capital with the National securities depository limited (NSDL) and the Central Depository Services (India) Limited (CDSL) and the total issued and listed equity share capital. The audit report confirms that the total issued / paid-up capital is in agreement with the total number of shares in physical form and the total number of dematerialised shares held with NSDL and CDSL.
- viii. **Code of Conduct**  
As per Regulation 17 of the SEBI Listing Regulations, the members of the board and senior management personnel have affirmed the compliance with the Code applicable to them during the year ended March 31, 2021. The Annual Report of the Company contains a Certificate by the CEO and Managing Director in terms of SEBI Listing Regulations on the compliance declarations received from Independent Directors, Non-executive Directors and Senior Management.
- ix. **A certificate has been received from Mr. Aqueel A Mulla, Practising Company Secretary, that none of the Directors on the Board of the Company has been debarred or disqualified from being appointed or continuing as directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such statutory authority.**
- x. **Shah & Savla LLP, Chartered Accountants (Firm Registration No. FRN: 109364W / W100143) has been appointed as the Statutory Auditors of the Company. The particulars of payment of Statutory Auditors' fees for FY 2021 is given below:**

Particulars	Amount (In Rs.)
Services as statutory auditors (including quarterly audits)	120,000.00
Other matters	13,500.00
<b>Total</b>	<b>133,500.00</b>

**VI. MEANS OF COMMUNICATION**

The quarterly, half-yearly and annual results of the Company are published in leading newspapers in India immediately after they are approved by the Board which include The Indian Express and Vadodara Samachar. The results are also displayed on the Company's website "[www.samratpharmachem.com](http://www.samratpharmachem.com)". A Management Discussion and Analysis Report is a part of this Integrated Annual Report.

**VII. GENERAL SHAREHOLDER INFORMATION**

## i. Annual General Meeting

AGM No.	29th Annual General Meeting
Date	30 September 2021
Time	1.00 p.m.
Venue	The Company is conducting meeting through VC / OAVM pursuant to the MCA Circular No. 20/2021 dated Jan 13, 2021 and as such there is no requirement to have a venue for the AGM.

## ii. Financial Calendar

Financial Year	<b>1 April 2020</b>	<b>To</b>	<b>31 March 2021</b>
----------------	---------------------	-----------	----------------------

## iii. Book Closure

The annual book closure period is from & to following dates, inclusive of both days.

Book Closure Date (From)	Book Closure Date (To)
Thursday, September 23, 2021	Thursday, September 30, 2021

## iv. Listing on Stock Exchanges

Name of the Stock Exchange	Stock Code	Address
BSE Limited (BSE)	530125	P. J. Towers, Dalal Street, Mumbai - 400 001, Maharashtra.

Listing fees as applicable have been paid.

## v. Corporate Identity number (CIN) of the Company

Corporate Identity Number	L24230GJ1992PLC017820
---------------------------	-----------------------

## vi. Market Price Data


Monthly high and low (based on daily closing prices) of Samrat Pharmachem Limited on BSE for the year ended 31st March, 2021

Month	High	Low	Total number of equity shares traded
April 2020	97.00	58.00	43,582
May 2020	83.00	65.00	28,679
June 2020	83.30	68.20	54,114
July 2020	105.00	70.15	121,966
August 2020	144.00	83.30	376,928
September 2020	126.00	98.05	119,315
October 2020	136.70	107.55	97,012
November 2020	126.00	100.00	53,912
December 2020	159.00	113.00	292,147
January 2021	139.00	116.25	56,640
February 2021	149.95	116.30	125,188
March 2021	155.10	125.00	88,122

Source: [www.bseindia.com/markets/equity/EQReports/StockPrcHistori.aspx](http://www.bseindia.com/markets/equity/EQReports/StockPrcHistori.aspx)

## vii. Performance of the share price of the Company

Month	Samrat Pharmachem (Closing Price)
Apr 2020	73.95
May 2020	72.40
Jun 2020	75.85
Jul 2020	92.40
Aug 2020	105.45
Sep 2020	114.00
Oct 2020	122.60
Nov 2020	111.25
Dec 2020	134.10
Jan 2021	118.85
Feb 2021	149.00
Mar 2021	136.00



viii. Registrars and share transfer agents :

Name	Link Intime India Private Limited
Address	C/101, 247 Park, LBS Marg, Vikhroli (West), Mumbai - 400 083.
Telephone	91-22-49186000
Fax	91-22-49186060
Contact Person (Client Relation Team)	Ms. Shweta Poojari
Email	rnt.helpdesk@linkintime.co.in
Website	www.linkintime.co.in

ix. Share transfer system:

88.21% of the equity shares of the Company are in electronic form. Transfers of these shares are done through the depositories with no involvement of the Company. Shares in physical form are processed by Registrar and Transfer Agent, M/s. Link Intime India Pvt. Ltd. The share transfers are processed within a period of 15 days from the date of receipt of the transfer documents by M/s Link Intime India Private Limited.




## x. Shareholding as on March 31, 2021

## a. Distribution of equity shareholding as on March 31, 2021

No. of Shares (From - To)	Number of Shareholders	Percentage of Shareholders	Number of Shares Held	Percentage of shares held
1 - 500	2,543	86.64	430,054	13.92
501 - 1000	210	7.16	165,953	5.37
1001 - 2000	96	3.27	145,615	4.71
2001 - 3000	28	0.95	73,756	2.39
3001 - 4000	11	0.37	39,769	1.29
4001 - 5000	14	0.48	65,116	2.11
5001 - 10000	13	0.44	103,670	3.36
10001 - *****	20	0.68	2,065,767	66.86
	2,935	100.00	3,089,700	100.00

## b. Categories of equity shareholders as on March 31, 2021

Category	Number of equity shares held	Percentage of holding
Promoters	1,523,233	49.30
Foreign Institutional Investors	100,000	3.24
Bodies Corporate	56,511	1.83
Individuals	1,311,273	42.44
HUF	34,091	1.10
Clearing Member	2,847	0.09
NRI (Non Repatriable)	3,492	0.11
NRI	58,253	1.89
<b>GRAND TOTAL</b>	<b>3,089,700</b>	<b>100.00</b>



## c. Top ten equity shareholders (Public) of the Company as on March 31, 2021

Sr. No.	Name of the Shareholder	Number of equity shares held	Percentage of holding
1	Mala R Bhavnani	188,706	6.11
2	Sangeetha S	105,000	3.40
3	Llyods Securities Overseas Limited	100,000	3.24
4	Anshul Specialty Molecules	41,246	1.33
5	Sharad Kanayalal Shah	35,000	1.13
6	Ashok Jain	24,345	0.79
7	Kishor Dhirajlal Sheth	18,750	0.61
8	Divyanshu Jayraj Kantol	12,500	0.40
9	Irfan Fakhri Karimi	12,056	0.39
10	Hetvi Nipun Mahida	10,175	0.33

## xi. Dematerialisation of shares and liquidity

The Company has arrangement with National Securities Depository Ltd. (NSDL) and Central Depository Services [India] Ltd. (CDSL) for demat facility. Under the Depository System, the International Securities Identification Number (ISIN) allotted to the Company's shares is INE103E01016.

Dematerialisation Status as on 31/03/2021	No. of Shares	Percentage of Capital
Held in dematerialised form in National Securities Depository Ltd. (NSDL)	2300286	74.45
Held in dematerialised form in Central Depository Services (I) Ltd. (CDSL)	425104	13.76
Physical	364310	11.79
<b>Total</b>	<b>3089700</b>	<b>100.00</b>

## xii. Outstanding GDRs / ADRs / Warrants or any convertible instruments, conversion date and likely impact on equity

The Company has not issued any GDRs / ADRs / Warrants or any convertible instruments in the past and hence, as on March 31, 2021, the Company does not have any outstanding GDRs / ADRs / Warrants or any convertible instruments.

## xiii. Commodity price risk or foreign exchange risk and hedging activities:

The Company does not deal in commodities and hence the disclosure pursuant to SEBI Circular dated November 15, 2018 is not required to be given. For a detailed discussion on foreign exchange risk and hedging activities, please refer to Management Discussion and Analysis Report.

xiv. Equity shares in the suspense account  
Nil

## xv. Plant Locations

- 1) Plot No. A2/3445, GIDC, Phase 4, Ankleshwar-393 002, Gujarat, India.
- 2) Plot No. A2/3444, GIDC, Phase 4, Ankleshwar-393 002, Gujarat, India.

xvi. Address for correspondence

Samrat Pharmachem Limited  
Plot No. A2/3445,  
GIDC, Phase 4,  
Ankleshwar - 393 002,  
Gujarat,  
India.  
Tel : 02646-220774  
Fax : 02646-251291  
Email: [contact@samratpharmachem.in](mailto:contact@samratpharmachem.in)  
Website: [www.samratpharmachem.com](http://www.samratpharmachem.com)

**By order of the Board of Directors  
For Samrat Pharmachem Limited**

**Place : Mumbai  
Date : 30 June 2021**

**Lalit Mehta  
Chairman & Managing Director  
DIN : 00216681**

**DECLARATION REGARDING COMPLIANCE BY BOARD MEMBERS AND SENIOR  
MANAGEMENT PERSONNEL WITH THE COMPANY'S CODE OF CONDUCT**

This is to confirm that the Company has adopted a Code of Conduct for its Senior Management Team including the Managing Director, Executive Directors and Non-Executive Independent Directors. These Codes are available on the Company's website.

I confirm that the Company has in respect of the year ended 31 March 2021, received from the Senior Management Team of the Company and the Members of the Board a declaration of compliance with the Code of Conduct as applicable to them.

**By order of the Board of Directors  
For Samrat Pharmachem Limited**

**Lalit Mehta  
Managing Director**

**Place : Mumbai  
Date : 30 June 2021**

**PRACTISING COMPANY SECRETARIES' CERTIFICATE ON CORPORATE  
GOVERNANCE**

**To the Members of  
Samrat Pharmachem Limited**

I have examined the compliance of the conditions of Corporate Governance by Samrat Pharmachem Limited ('the Company') for the year ended on March 31, 2021, as stipulated under Regulations 17 to 27, clauses (b) to (i) of sub-regulation (2) of Regulation 46 and para C, D and E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

The compliance of the conditions of Corporate Governance is the responsibility of the management of the Company. My examination was limited to the review of procedures and implementation thereof, as adopted by the Company for ensuring compliance with conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In my opinion and to the best of my information and according to the explanations given to me, and the representations made by the Directors and the Management and considering the relaxations granted by the Ministry of Corporate Affairs and Securities and Exchange Board of India warranted due to the spread of the COVID-19 pandemic, I certify that the Company has complied with the conditions of Corporate Governance as stipulated in the SEBI Listing Regulations for the year ended on March 31, 2021.

I further state that such compliance is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

**Place : Mumbai  
Date : 30 June 2021**

**For A.A. Mulla &  
Associates  
Company Secretaries**

**Aqueel A. Mulla  
Proprietor  
FCS NO. 2973  
C.P. No.3237  
UDIN : F002973C000547352**

**CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS****as on financial year ended on March 31, 2021**

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,  
The Members  
**Samrat Pharmachem Limited**  
Plot No. A2/3445,  
GIDC- Phase 4,  
Ankleshwar-393002,  
Gujarat.

I have examined the relevant registers, records, forms, returns and disclosures received from the Directors of **Samrat Pharmachem Limited** having CIN: **L24230GJ1992PLC017820** and having registered office at Plot No. A2/3445, GIDC- Phase 4, Ankleshwar-393002, Gujarat. (hereinafter referred to as 'the Company'), produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C clause 10(i) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In my opinion and to the best of my information and according to the verifications (including Directors Identification Number (DIN) status at the portal [www.mca.gov.in](http://www.mca.gov.in)) as considered necessary and explanations furnished to me by the Company & its officers, I hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2021 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India or Ministry of Corporate Affairs.

Sr No.	Name of Director	DIN	Date of Appointment as director
1	Lalit Damodar Mehta	00216681	16/06/1992
2	Rajesh Lalit Mehta	00216731	01/04/2008
3	Megh Rajesh Mehta	07287397	01/10/2015
4	Samir Harsukhrai Kothary	00216603	30/07/2003
5	Mahendra Indulal Pipalia	00216959	17/03/2003
6	Renu Piyush Dharod	07063088	14/02/2015

Ensuring the eligibility for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

**For A.A. Mulla & Associates**  
**Company Secretaries**

**Place : Mumbai**  
**Date : 30 June 2021**

**Aqueel A. Mulla**  
**Proprietor**  
**FCS NO. 2973**  
**C.P. No.3237**  
**UDIN : F002973C000547297**

**CERTIFICATION BY MANAGING DIRECTOR****The Board of Directors****Samrat Pharmachem Limited**

Plot No. A2/3445,  
GIDC, Phase 4,  
Ankleshwar - 393 002,  
Gujarat.

I, Mr. Lalit Mehta, Managing Director of Samrat Pharmachem Limited certify to the Board, that I have reviewed the financial statement and cash flow statement of the company for the financial year ended 31 March 2021.

- 1 To the best of my knowledge, I certify that:
  - a) these statements do not contain any materially untrue statement or omit any material fact or contain statements that are misleading
  - b) these statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards, applicable laws and regulations, and
  - c) there are no transactions entered into by the company during the year which are fraudulent, illegal or violative of the company's code of conduct
- 2 For the purposes of financial reporting, I accept the responsibility for establishing and maintaining internal controls and that I have evaluated the effectiveness of the internal control systems of the company pertaining to financial reporting and I accept the responsibility to the auditors and the audit committee, and further state that there were no deficiencies in the design or operation such internal control.
- 3 I do further certify that there has been:
  - a) no significant changes in internal controls during the year
  - b) no significant changes in accounting policies during the year, and
  - c) no instances of fraud, of which I am aware during the period
- 4 I further declare that all Board members and senior managerial personnel have affirmed compliance with the code of conduct for the current year.

**By order of the Board of Directors  
For Samrat Pharmachem Limited**

**Lalit Mehta  
Managing Director**

**Place : Mumbai  
Date : 30 June 2021**

**CERTIFICATION BY CHIEF FINANCIAL OFFICER (CFO)**

I, Mr. Rajesh Mehta, Chief Financial Officer (CFO), of Samrat Pharmachem Limited, to the best of my knowledge and belief, certify that:-

1. I have reviewed the Balance Sheet and Profit and Loss account (Standalone) for the financial year ended 31 March 2021 and all its schedules and notes on accounts, as well as the Cash Flow Statements and the Directors' Report and annexure thereto.
2. Based on my knowledge and information, these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.
3. Based on my knowledge and information, these statements together present true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
4. To the best of my knowledge and belief, no transactions entered into by the Company during the year are fraudulent, illegal or violative of the Company's Code of Conduct.
5. The Company's other certifying officers and I, are responsible for establishing and maintaining disclosure controls and procedures for the Company, and we have:-
  - a) Designed such disclosure controls and procedures to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and
  - b) Evaluated the effectiveness of the Company's disclosure, controls and procedure.
6. The Company's other certifying officers and I, have disclosed based on our most recent evaluation, wherever applicable, to the Company's auditors and audit committee of the Company's Board of Directors (and persons performing the equivalent functions):
  - a) All significant deficiencies in the design or operation of internal controls;
  - b) All significant changes in internal control during the year;
  - c) All significant changes in accounting policies during the year and the same have been disclosed in the notes to the financial statements; and
  - d) Instances of significant fraud, if any, of which we are aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system.
7. I further declare that all Board members and senior management personnel have affirmed Compliance with the Code of Conduct for Board and Senior Management Personnel for the current year.

**By order of the Board of Directors  
For Samrat Pharmachem Limited**

**Rajesh Mehta  
Chief Financial Officer**

**Place : Mumbai  
Date : 30 June 2021**



## **MANAGEMENT DISCUSSION AND ANALYSIS**

### **INDUSTRY STRUCTURE AND DEVELOPMENTS**

Your Company is a producer of pharmaceutical chemicals. The intermediates produced are used in pharmaceutical and chemical industries. Your Company is amongst the manufacturers who produce for local and international needs of the pharmaceuticals and chemicals industry. The pharmaceutical and chemical industry is growing at a rapid pace every year. This results into growth of the support or intermediate industry like us.

### **OPPORTUNITIES AND THREATS**

The company looks forward optimistically for all round growth in turnover & profitability in the ensuing years. Your company has taken effective steps to realize the dream performance in the years to come. The company intends to double its turnover in a short period of time. The company has taken effective measures to improve quality of products and its productivity to outwit competitor from domestic and international market.

The company has registered good sales growth & earned reasonable profit during the current financial year. The company has plans to widen the product range by increasing the basket of products thereby enlarging the customer and sales base.

### **PRODUCT PERFORMANCE**

The company has two plants producing varied items. The basic purpose of producing in two different plants is to improve efficiency and manageability. Your Company shall achieve sustainable growth in both plants by modernization and automation of operations. According to your Directors, these plants facilitate better division of labour, enable us to develop expertise in each plant and their respective items, and hence improve productivity and profitability of the Company.

### **BUSINESS OUTLOOK**

The Indian pharmaceutical industry is the world's third largest in terms of volume and ranks 11th in terms of value. It is among the faster-growing markets and the largest exporter of generic drugs by volume. Outside of the US, India has the largest number of USFDA-approved pharmaceutical manufacturing facilities. Over the last year, India played a crucial role in supplying therapeutic drugs for COVID-19 treatment across the world and is also one of the key manufacturers of some of the COVID-19 vaccines. Going forward, India is likely to maintain a leadership position in the manufacture and supply of high-quality generic medicines as well as a major manufacturer of COVID-19 vaccines. The Indian pharmaceutical market recorded ~9.5% CAGR between 2016-20 to reach US\$21 Billion. It is expected to grow at 8-11% CAGR to US\$29-33 Billion by 2025. The COVID-19 pandemic has resulted into enhancement of capacity utilization and growth in CAPEX in the pharmaceutical industry world over.

### **RISKS AND CONCERNS**

#### Currency Risk:

Volatility in currency exchange movements results in transaction and translation exposure. Our functional currency is the Indian Rupee. Appreciation of the Rupee against any major currency could impact the reported revenue in Rupee terms, the profitability and also result in collection losses.

Following a currency hedging policy that is aligned with market best practices, to limit impact of exchange volatility on receivables and payables, forecasted revenue and other current assets and liabilities. Hedging strategies are decided and monitored by the Risk Management Committee of the Board convened on a regular basis.

**Competition Risk :** We feel that the major business risks are the stiff competition due to low priced products from countries like China and also from domestic manufacturers for certain products. However the company is trying to expand its range of products to cater to different segment of customers and market in order to absorb fall in sales and margins.

**Credit Risk :** We have been able to reduce the irrecoverable amounts to a very negligible level, notwithstanding the inevitability of having some debts which are not recoverable. Due to strict monitoring and disciplined distribution channels, we do not foresee any material risk on this count.

**Dead Stocks/Slow moving items/Rejections Risk :** Sometimes the quality of finished product becomes bad or is rejected by a customer. The Company has taken every step in the raw material procurement stage, production stage, packing stage, testing stage and delivery stage to minimize the risk of rejection. If due to some unforeseen reasons the goods are rejected or are not as per our in-house standards, the company has made a system to reprocess all such failed material. Minimum cost is incurred to make them into acceptable standards again. Further the products that have irregular demand or are sold in lesser quantities round the year are manufactured as per customers order only. Thus the company is successful in handling dead stocks, slow moving items and rejections.

**Fire, Theft & Explosion Risk :** The Company has been quite conscious of the inherent risk in our business. A lot of measures to safeguard the fixed assets and stocks in the factory are taken. The management has been regularly updating the risk profile and take necessary corrective steps like educating workers, insisting workers to wear gum boots, gloves, eye goggles, helmets etc, installing fire fighting equipments, putting sign boards, banning smoking in the premises, keeping hazardous materials in a safe and protected place etc. Apart from these measures, the company has also underwritten the various risks like fire, theft & burglary, earthquake, floods, riots, public liability, sale/purchase in transit etc with ICICI Lombard General Insurance Co Ltd.

## INTERNAL CONTROL SYSTEM AND ITS ADEQUACY

The Company has instituted adequate internal controls, managed by professionals. The control mechanism duly supported by efficient integrated software ensures a proper documentation, accounting, reporting and safeguarding of assets. The Company has also well defined and established system of internal audit, which is periodically reviewed by the audit committee and steps taken to strengthen the control measures. The management and audit committee of the Board periodically reviews the observations and findings of the statutory auditors and ensures adherence to the well laid down policies, guidelines and procedures forming part of the internal control system.

## FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE

A satisfactory business performance with average volume growth in key products and business units, combined with productivity improvement, cost management and working capital management have contributed to the good operating results for the year. Also sharp focus on cost and margins has resulted in enhanced operational efficiency.

### Financial Performance

#### Income Statement (₹) in Crores

Particulars	31/03/2021	31/03/2020	31-03-19	31-03-18	31-03-17
Revenue	179.02	137.45	111.14	92.52	71.14
Other Income	0.46	0.57	0.46	0.25	0.07
Total Income	179.48	138.03	111.59	92.77	71.21
Expenditure	-171.64	-131.81	-109.52	-87.43	-68.02
Interest	-1.28	-0.98	-1.06	-0.86	-0.68

PBDT	7.84	6.21	2.58	5.33	3.19
Depreciation	-0.49	-0.43	-0.42	-0.41	-0.70
PBT	7.34	5.79	2.16	4.92	2.49
Tax	-2.01	-1.55	-0.62	-1.70	-0.93
Net Profit	5.33	4.24	1.54	3.22	1.57
Equity	3.09	3.09	3.09	3.09	3.09
EPS	17.26	13.71	4.97	10.41	5.07
CEPS	18.85	15.09	6.32	11.74	7.32
OPM %	5.09	4.52	2.32	5.76	4.48
NPM %	2.98	3.08	1.38	3.48	2.20

Source: <https://www.bseindia.com/stock-share-price/financials/results/530125>

### MATERIAL DEVELOPMENT IN HUMAN RESOURCES/INDUSTRIAL RELATIONS FRONTS

The industrial relations have been satisfactory in the Registered Office Cum Factory and at the Corporate Office. There was loss of man-days due to COVID-19 pandemic manufacturing premises had remained shut for a few days during the start of financial year & office remained closed throughout lockdown period which affected industrial activities. A lot of initiatives have been undertaken by the Human Resource Department during the year. Apart from improvement in the system to align the compensation to the performance of the employees, steps are being taken by the management to provide training both in-house and at recognized institutes to enhance the effectiveness of the employees. Steps are also being taken to focus on managerial and behavioural competence across the organization. Information Technology has been a focused area for improving the operational efficiency and as a tool for decision-making.

### CAUTIONARY STATEMENT

Statement in the report of Management Discussion and Analysis describing the Company's objectives, projections, estimates, expectations or predictions may be "forward looking statements" within the meaning applicable securities laws or regulations. These statements are based on certain assumptions and expectations for future events. Actual results could differ materially from those of future events. Actual results could differ materially from those expressed or implied. Important factors that could make a difference to the Company's operations include economic conditions affecting global and domestic demand supply, finished goods prices in the domestic and overseas market in which the Company operates, raw materials cost and availability, changes in Government regulations, tax regimes, economic developments within India and other factors such as litigation and industrial relations. The Company assumes no responsibility to publicly amend, modify or revise and forward looking statements, on the basis of any subsequent development, information or events.

**By order of the Board of Directors  
For Samrat Pharmachem Limited**

**Place : Mumbai  
Date : 30 June 2021**

**Lalit Mehta  
Chairman & Managing Director  
DIN : 00216681**

**Independent Auditor`s Report**

**To the Members of,  
Samrat Pharmachem Limited**

**Report on the Financial Statements****Opinion**

We have audited the accompanying financial statements of Samrat Pharmachem Limited ('the Company'), which comprise the Balance Sheet as at 31st March 2021, the Statement of Profit & Loss (including the Other Comprehensive Income), the Cash Flow Statement and the Statement of Changes in Equity of the Company for the year then ended and notes to the financial statements including summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ('Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including Indian Accounting Standards ('Ind AS') specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) rules, 2015 as amended, and other accounting principles generally accepted in India, of the state of affairs (financial position) of the Company as at 31st March 2021, and its profit (financial performance including other comprehensive income), its cash flows and the changes in equity for the year ended on that date.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on financial statements.

**Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined the matter described below to be the key audit matters to be communicated in our report.

**a) Revenue Recognition :**

The Company has adopted "Ind-AS 115 - Revenue from Contracts with Customers" which is the revenue accounting standard. The application and transition to this accounting standard is complex and is an area of focus in the audit.

- Revenue for the Company consists primarily of sale of manufactured goods recognized as per the accounting policy described in Note 2(m) to the accompanying financial statements.
- The Company recognises revenue from sale of goods when it satisfies its performance obligation, in accordance with the principles of Ind-AS 115, Revenue from Contracts with Customers, adopted by the Company from the current year, by transferring the control of goods to its customers through delivery evidenced by acknowledgement of receipt of goods by such customers.
- Considering the large volume of revenue transactions near period end there may be a risk of revenue recognition occurring before the satisfaction of the performance obligations by the company in accordance with the applicable Incoterms.
- Considering the above factors, revenue recognition was identified as a key audit matter for the current year audit.

**Auditors Response:****Principal Audit Procedure**

Our audit work included, but was not limited to, the following procedures:

- Obtained an understanding of the revenue and receivable business process, and assessed the appropriateness of the accounting policy adopted by the company for revenue recognition.
- Evaluated design and implementation of the key controls around revenue recognition including controls around contract approvals, invoice verification, transporter confirmations and customer acknowledgements.
- Tested operating effectiveness of the above identified key controls over revenue recognition near period end.
- For samples selected from revenue recorded during specific period, before and after year end:
  - o Verified the customer contracts for delivery terms.
  - o Verified the customer acknowledgements to evidence proof of delivery for domestic sales at or near period end and
  - o tracked shipments through bill of lading for export sales
- Tested the appropriateness of the disclosures made in the financial statements for revenue recorded during the year.

**Key Observations**

- Based on our audit work, we did not identify any evidence of material misstatement in the revenue recognised in the year ended on 31 March 2021.

**b) Litigation, claims and related provisions:**

The company is in the pharmaceutical industry which is heavily regulated, resulting in increased exposure to litigation risk. These provisions are based on judgement and incorporated accounting estimates by management in determining the likelihood and magnitude of an unfavorable outcome on the claims.

**Auditors response:**

Evaluating the design and testing the operating effectiveness of controls in respect of the recognition and measurement of provisions towards litigation and claims in compliance with Ind-AS 37 Provisions, Contingent Liabilities and Contingent Assets.

Corroborating management's assessment by

- making enquiries with the in-house/outourced legal counsel of the company;
- verifying correspondence, orders and appeals in respect of open litigation;
- Obtaining confirmations from external legal counsels where relevant and/ or evaluating legal opinions obtained by the management.

**c) Property, Plant and Equipments:**

Peculiarity and technical complexities of Property, Plant and Equipments, Capital Work-In-Progress used in the operations and different IT systems used for maintaining Fixed Asset Register (FAR) requires more attention to ensure reasonably accurateness and completeness of financial reporting in respect of Property, Plant and Equipments and Capital W.I.P.

Further, due to technical complexities management is required to assess and make estimates/judgments about capitalization, estimated useful life, impairment etc. which has material impact on Balance Sheet and operating results.

**Auditors Response :**

Our audit approach consisted of testing of the design and operating effectiveness of the internal controls and substantive testing as follows:

- We assessed the Company's process regarding maintenance of records, Valuation and accounting of transactions relating to Property, Plant and Equipment and Capital W.I.P. as per the Ind-AS 16
- We have carried out substantive audit procedures at financial and assertion level to verify the capitalization of asset as Property, Plant and Equipment and Capital W.I.P.
- We have verified the maintenance of records and accounting of transactions regarding capital work in progress by carrying out substantive audit procedures at financial and assertion level.
- We have reviewed management judgement pertaining to estimation of useful life and depreciation of the Property, Plant and Equipment in accordance with Schedule II of Companies Act, 2013.
- We have verified the capitalization of borrowing cost incurred on qualifying asset in accordance with the Ind-AS 23 Borrowing Cost.

**d) Inventory**

Inventories constitutes material component of financial statement. Correctness, completeness and valuation are critical for reflecting true and fair financial results of operations.

**Auditors Response:**

Our audit approach consisted testing of the design and operating effectiveness of the internal controls and substantive testing as follows:

- We assessed the Company's process regarding Maintenance of records, Valuation and accounting of transactions relating to Inventory as per the Ind-AS 2.
- We have evaluated the design of Internal Controls relating to recording and valuation of Inventory.
- We have carried out substantive audit procedures at financial and assertion level to verify the allocation of overheads to Inventory.
- We have verified the process documents in respect of the physical verification of Inventory carried out by the management to verify the balance of the inventory at the year end.
- We have verified the compliance with the standard norms relating to production as framed and timely updated by the management.

**Information Other than the Financial Statements and Auditors' Report Thereon**

The Company's Management and Board of Directors are responsible for the other information. The other information comprises of Management Reports such as Board's Report, Management Discussion and Analysis, Corporate Governance Report and Business Responsibility Report, but does not include the Financial Statements and our Auditors' Report thereon which we obtained prior to the date of this Auditor's Report, and the remaining section of the Company's Annual Report, which are expected to be made available to us after that date.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information that we obtained prior to the date of this Auditor's Report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

When we read the other sections of Annual Report (other than those mentioned above), if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and take necessary actions, as applicable under the applicable laws and regulations.

**Management's Responsibility for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 (the 'Act') with respect to the preparation and presentation of these financial statements that give a true and fair view of the financial position, financial performance (including Other Comprehensive Income), Cash Flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind-AS) specified under Section 133 of the Act, read with relevant rules issued thereunder.

This responsibility also includes the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

#### **Auditor's Responsibility for the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the financial statements made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report.



However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### **Report on Other Legal and Regulatory Requirements**

- 1 As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the 'Annexure A', a statement on the matters specified in the paragraph 3 and 4 of the Order, to the extent applicable.
- 2 As required by section 143 (3) of the Act, we report that:
  - i. we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
  - ii. in our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books;
  - iii. the Balance Sheet and the Statement of Profit and Loss (including other comprehensive income), the statement of changes in equity and the statement of Cash Flow Statement dealt with by this Report are in agreement with the books of account;
  - iv. in our opinion, the aforesaid financial statements comply with the Indian Accounting Standards prescribed under Section 133 of the Act, read with relevant rules issued thereunder;
  - v. on the basis of written representations received from the directors as on 31st March 2021, and taken on record by the Board of Directors, none of the directors are disqualified as on 31st March 2021, from being appointed as a director in terms of Section 164 (2) of the Act.
  - vi. with respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate report in 'Annexure B'; and

- vii. With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of Section 197(16) of the Act, amended:

In our opinion and according to the information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under section 197 916) which are required to be commented upon by us.

- viii. with respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- a) the Company has disclosed the impact of pending litigations on its financial positions in its financial statements. Refer to Note 42 to the financial statements.
- b) the Company did not have any long term contracts including derivative contracts for which there were any material foreseeable losses.
- c) Since the company has not declared any dividend in the recent past years, no amounts are required to be transferred by the company to Investor Education & Protection Fund.

**For Shah & Savla LLP**  
**Chartered Accountants**  
**FRN: 109364W / W100143**

**Miral H. Nagda**  
**Partner**  
**Membership No.: 108135**

**UDIN : 21108135AAAACE5295**  
**Place : Mumbai**  
**Date : 30 June 2021**

**Annexure A to the Auditors' Report**

The Annexure referred to in our report to the members of Samrat Pharmachem Limited ('the Company') for the year Ended on 31st March, 2021. We report that:

- (i) a) The company is maintaining proper records showing full particulars, including quantitative details and situation of fixed assets on the basis of available information.
- b) As explained to us substantial portion of the fixed assets have been physically verified by the management in a phased periodical manner, which in our opinion is reasonable having regard to the size of the company and nature of its fixed assets. As informed to us no material discrepancies were noticed on such physical verification.
- c) As per the information and explanation provided to us and as per the records presented before us the title deeds of immovable properties are held in the name of the company.
- (ii) In our opinion the inventories have been physically verified by the management during the year at reasonable intervals and as explained to us no material discrepancies were observed on physical verification.
- (iii) The company has not granted any amount as loan to person covered in the Register maintained under Section 189 of the Act and hence the sub-clauses dealing with the said reporting are not applicable.
- (iv) As per the information and explanation given to us, the company has not granted any loans to directors of the company and company has not made any investment through more than two layers of investment companies. Thus, the said clause is not applicable to the company.
- (v) According to information and explanations given to us, the Company has not accepted any deposits from the public. Accordingly, paragraph 3(v) of the order is not applicable to the Company.
- (vi) We have been informed by the management that the Central Government of India has not prescribed the method of maintenance of cost records under sub-section (1) of Section 148 of the Act and the rules framed there under.
- (vii) a) According to the information and explanations given to us and on the basis of our examination of the records of the company, undisputed statutory dues including Income-Tax, Sales-tax, Goods and Services tax, Custom duty, Excise duty and Value Added Tax, Cess and other material statutory dues applicable to it have generally been deposited with the appropriate authorities regularly.

According to the information and explanations given to us, no undisputed amounts payable in respect of the aforesaid dues were outstanding, as at 31st March, 2021 for period of more than six months from the date they became payable.

- b) According to the information and explanations given to us, the details of dues of Income Tax, Sales Tax, Goods and Service Tax, Customs Duty, Excise Duty and Value Added Tax which have not been deposited as on March 31, 2021 on account of disputes are given below :-

Sr. No.	Name of the Statute	Nature of Dues	Amount (in Rs.)	Period to which amount relates	Forum where dispute is pending
1	Income Tax Act, 1961	Income tax	715740	A.Y. 2011-12	CIT(Appeals), Bharuch

- (viii) In our opinion and according to the information and explanations given to us, the company has not defaulted in repayment of dues to financial institution, banks. The Company did not have any debentures outstanding as at the year end.
- (ix) We have been informed by the management that during the period covered by our audit report, the company did not raise any money by way of initial public offer or further public offer (including debt instruments) and Term Loans.
- (x) According to the information and explanations given to us, no material fraud by the Company or on the Company by its officers or employees has been noticed or reported during the course of our audit.
- (xi) In our opinion and according to information and explanations given to us the Company has paid/provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of Section 197, read with limits specified under Part II of Schedule V to the Act.
- (xii) In our opinion and according to the information and explanations given to us, the Company is not a Nidhi company. Accordingly, paragraph 3 (xii) of the order is not applicable.
- (xiii) As per the information and explanations given to us & represented by the management, we report that all the transactions with related parties are in compliance with Section 177 and 188 of Companies Act, 2013 where applicable and the details of such transactions have been disclosed in the financial statements as required by the Indian accounting standards.
- (xiv) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, paragraph 3(xiv) of the order is not applicable to the Company.
- (xv) As per the information and explanations given to us & represented by the management, during the year the company has not entered into any non-cash transactions with its directors or persons connected with him. Accordingly, paragraph 3(xv) of the order is not applicable to the Company.
- (xvi) According to the information and explanation given to us, the Company is not required to be registered under Section 45– IA of the Reserve Bank of India Act, 1934.

**For Shah & Savla LLP**  
**Chartered Accountants**  
**FRN: 109364W / W100143**

**Miral H. Nagda**  
**Partner**  
**Membership No.: 108135**  
**UDIN : 21108135AAAACE5295**  
**Place : Mumbai**  
**Date : 30 June 2021**

**Annexure B to the Auditors' Report****Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)****Opinion**

We have audited the internal financial controls with reference to financial statements of Samrat Pharmachem Limited (“the Company”) as of 31st March, 2021 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such internal financial controls were operating effectively as at 31st March, 2021, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the “Guidance Note”).

**Management’s Responsibility for Internal Financial Controls**

The Company’s Management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

**Auditors’ Responsibility**

Our responsibility is to express an opinion on the Company’s internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and whether such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls with reference to financial statements.

**Meaning of Internal Financial Controls with reference to Financial Statements**

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

**Inherent Limitations of Internal Financial Controls with reference to Financial Statements**

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

**For Shah & Savla LLP**  
**Chartered Accountants**  
**FRN: 109364W / W100143**

**Miral H. Nagda**  
**(Partner)**  
**Membership No.: 108135**

<b>UDIN :</b>	<b>21108135AAAACE5295</b>
<b>Place :</b>	<b>Mumbai</b>
<b>Date :</b>	<b>30 June 2021</b>

**BALANCE SHEET AS AT 31 MARCH, 2021**

	Particulars	Note No.	31-Mar-2021		31-Mar-2020	
			Rs.	Rs.	Rs.	Rs.
<b>A</b>	<b><u>ASSETS</u></b>					
<b>1</b>	<b>Non-Current Assets</b>					
	Property, Plant and Equipment	3	93,939,411		71,814,654	
	Capital work-in-progress	3	-		10,808,416.38	
	Intangible assets	3	94,185		38,529	
	Intangible assets under development	3	-		-	
	Financial Assets					
	Investments		-		-	
	Loans	4	2,046,500		1,687,000	
	Deferred tax assets (net)		-		-	
	Other non-current assets	5	4,646,120		2,332,545	
	<b>Total Non-current assets</b>			<b>100,726,216</b>		<b>86,681,144</b>
<b>2</b>	<b>Current Assets</b>					
	Inventories	6	113,998,658		187,673,586	
	Financial Assets					
	Investments	7	10,000		10,000	
	Trade Receivables	8	330,054,234		278,128,141	
	Cash and Cash Equivalents	9	25,425,565		11,718,621	
	Loans	10	180,000		234,000	
	Other Financial Assets	11	-		-	
	Other current assets	12	3,569,991		19,040,482	
	<b>Total Current Assets</b>			<b>473,238,448</b>		<b>496,804,831</b>
	<b>Total Assets</b>			<b>573,964,664</b>		<b>583,485,975</b>
<b>B</b>	<b><u>EQUITY AND LIABILITIES</u></b>					
<b>1</b>	<b>Equity</b>					
	Equity Share capital	13	30,897,000		30,897,000	
	Other Equity	14	265,471,531		212,139,743	
	<b>Total Equity</b>			<b>296,368,531</b>		<b>243,036,743</b>
<b>2</b>	<b>Liabilities</b>					
<b>(a)</b>	<b>Non-Current Liabilities</b>					
	Financial Liabilities					
	Borrowings	15	-		-	
	Provisions		-		-	
	Deferred Tax Liabilities (Net)	16	4,325,581		1,447,879	
	Other Non-Current Liabilities	17	-		-	
	<b>Total Non-Current liabilities</b>			<b>4,325,581</b>		<b>1,447,879</b>

(b)	<b>Current Liabilities</b>					
	Financial Liabilities					
	Borrowings	18	87,936,611		90,966,870	
	Trade Payables	19	176,602,236		231,461,278	
	Other Financial Liabilities		-		-	
	Other Current Liabilities	20	1,708,812		4,389,273	
	Provisions	21	7,022,893		12,183,933	
	<b>Total Current Liabilities</b>			<b>273,270,552</b>		339,001,353
	<b>Total Liabilities</b>			<b>573,964,664</b>		583,485,975
	Contingent Liabilities & Commitments	1 to				
	Notes to the Financial Statements	48				
AS PER OUR REPORT OF EVEN DATE						
For Shah & Savla LLP			FOR AND ON BEHALF OF THE BOARD OF DIRECTORS			
Chartered Accountants						
			Lalit Mehta	Rajesh Mehta	Megh Mehta	
			Managing Director	Executive Director	Executive Director	
			[DIN: 00216681]	[DIN: 00216731]	[DIN: 07287394]	
Miral H. Nagda						
Partner						
Membership No.: 108135						
FRN: 109364W / W100143						
Place : Mumbai			Mahendra Pipalia	Samir Kothary	Renu Dharod	
Date : 30 June 2021			Director	Director	Director	
			[DIN: 00216959]	[DIN: 00216603]	[DIN: 07063088]	



## PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31 MARCH, 2021

	Particulars	Note No.	31-Mar-2021		31-Mar-2020	
			Rs.	Rs.	Rs.	Rs.
<b>A.</b>	<b>Revenue from operations</b>	22		1,790,177,828		1,374,524,757
<b>B.</b>	<b>Other income</b>	23		4,628,134		5,721,509
<b>C.</b>	<b>Total Revenue</b>			1,794,805,962		1,380,246,267
<b>D.</b>	<b>Expenses</b>					
	Cost of Material Consumed	24	1,620,175,980		1,317,980,354	
	Purchase of Traded Goods		-		-	
	Changes in inventories of FG, WIP & Traded goods	25	22,275,077		-61,805,647	
	Employee benefits expense	26	14,980,251		14,439,360	
	Finance costs	27	12,766,728		9,783,321	
	Depreciation and amortization expense	3	4,928,617		4,262,541	
	Other expenses	28	46,063,519		37,616,235	
	<b>Total expenses</b>			1,721,190,172		1,322,276,164
<b>E.</b>	<b>Profit before exceptional and extraordinary items and tax</b>			73,615,791		57,970,102
<b>F.</b>	<b>Exceptional items</b>			176,807		120,212
<b>G.</b>	<b>Profit before extraordinary items and tax</b>			73,438,984		57,849,890
<b>H.</b>	<b>Extraordinary Items</b>			-		-
<b>E.</b>	<b>Profit before tax</b>			73,438,984		57,849,890
<b>F.</b>	<b>Tax expense:</b>					
	Provision for Taxation					
	- Current Tax		17,204,493		17,200,473	
	- Taxation of Earlier Years		25,000		50,996	
	- Deferred Tax		2,877,702		-1,769,083	
	<b>Total Tax</b>			20,107,195		15,482,386
<b>G.</b>	<b>Profit (Loss) for the period</b>			53,331,789		42,367,504
<b>H.</b>	<b>Other Comprehensive Income</b>			-		-

I.	Total Comprehensive Income for the period			53,331,789		42,367,504
J.	Earnings per equity share:					
	(1) Basic			17.26		13.71
	(2) Diluted			17.26		13.71
	Notes to the Financial Statements	1 to 48				

AS PER OUR REPORT OF EVEN DATE

For Shah & Savla LLP  
Chartered Accountants

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS

Lalit Mehta

Rajesh Mehta

Megh Mehta

Managing Director  
[DIN: 00216681]Executive Director  
[DIN: 00216731]Executive Director  
[DIN: 07287394]Miral H. Nagda  
PartnerMembership No.: 108135  
FRN: 109364W / W100143

Place : Mumbai

Date : 30 June 2021

Mahendra Pipalia  
Director  
[DIN: 00216959]Samir Kothary  
Director  
[DIN: 00216603]Renu Dharod  
Director  
[DIN: 07063088]

**STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 MARCH, 2021**

Particulars	Equity share capital	Retained Earnings	Other Comprehensive Income	Total Other Equity
<b>Balances at 31 Mar 2019</b>	<b>30,897,000</b>	<b>169,772,239</b>	-	<b>169,772,239</b>
Transfer from statement of profit and loss	-	42,367,504	-	42,367,504
Other comprehensive income	-	-	-	-
<b>Balances at 31 Mar 2020</b>	<b>30,897,000</b>	<b>212,139,743</b>	-	<b>212,139,743</b>
Transfer from statement of profit and loss	-	53,331,789	-	53,331,789
Dividend declared	-	-	-	-
Dividend distribution tax	-	-	-	-
Other comprehensive income	-	-	-	-
<b>Balances at 31 Mar 2021</b>	<b>30,897,000</b>	<b>265,471,531</b>	-	<b>265,471,531</b>

For Shah & Savla LLP  
Chartered Accountants

Miral H. Nagda  
Partner

Membership No.: 108135  
FRN: 109364W / W100143

Place : Mumbai  
Date : 30 June 2021

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS

Lalit Mehta  
Managing Director  
[DIN: 00216681]

Mahendra Pipalia  
Director  
[DIN: 00216959]

Rajesh Mehta  
Executive Director  
[DIN: 00216731]

Samir Kothary  
Director  
[DIN: 00216603]

Megh Mehta  
Executive Director  
[DIN: 07287394]

Renu Dharod  
Director  
[DIN: 07063088]

**Note :****1 GENERAL INFORMATION**

Samrat Pharmachem Limited is a public limited company domiciled in India incorporated under the provisions of the Companies Act ( 'the Company'). The Company's principal activities are manufacturing and selling chemicals. The shares of the Company are listed on stock exchanges in India.

**2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND OTHER EXPLANATORY INFORMATION****a Basis of Preparation**

The financial statements of the Company have been prepared and presented in accordance with Indian Accounting Standards (Ind AS) as per Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standard) Amendment Rules, 2016 as notified under section 133 of Companies Act, 2016 (the "Act") and other relevant provisions of the Act.

The standalone financial statements of the Company are prepared in accordance with Indian Accounting Standards (Ind AS) under the historical cost convention on accrual basis except for certain financial assets and financial liabilities that have been measured at fair value. These standalone financial statements are presented in Indian Rupees which is also the Company's functional currency. Figures for the previous years have been regrouped/rearranged wherever considered necessary to conform to the figures presented in the current year.

**b Use of Estimates**

The preparation of financial statements requires management to make judgments, estimates and assumptions of some of the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities on the date of the financial statements and the amount of revenue and expenses during the period reported. However any revision to accounting estimates or difference between the actual results and estimates are recognized prospectively in the period in which the result are known/ materialized.

**c Property, Plant and Equipment****Land**

Land (other than investment property) held for use in production or administration is stated at cost. As no finite useful life for land can be determined, related carrying amounts are not depreciated.

**Buildings and other equipment**

Buildings and other equipment (comprising plant and machinery, furniture and fittings, electrical equipment, office equipment, computers and vehicles) are initially recognized at acquisition cost, including any costs directly attributable to bringing the assets to the location and condition necessary for them to be capable of operating in the manner intended by the management. Buildings and other equipment are subsequently measured at cost less accumulated depreciation and any impairment losses. Cost of property, plant and equipment not ready for the intended use before reporting date is disclosed as capital work in progress. Subsequent expenditure incurred on an item of property, plant and equipment is added to the book value of that asset only if this increases the future benefits from the existing asset beyond its previously assessed standard of performance. Gains or losses arising on the disposal of property, plant and equipment are determined as the difference between the disposal proceeds and the carrying amount of the assets and are recognized in the statement of profit and loss within other income or other expenses. The components of assets are capitalized only if the life of the components vary significantly and whose cost is significant in relation to the cost of respective asset. The life of components in assets are determined based on technical assessment and past history of replacement of such components in the assets. Tangible assets are carried at the cost of acquisition or construction less accumulated depreciation and accumulated impairment, if any. The cost of tangible assets includes non-refundable taxes, duties, freight and other incidental expenses related to

the acquisition and installation of the respective assets. Assets which are retired from active use and are held for disposal are stated at the lower of their net book value or net realizable value. Cost of tangible assets, not ready for the intended use as at balance sheet date, are disclosed as “capital work in progress”.

**Intangible assets** are carried at cost less accumulated amortisation and impairment losses, if any. The cost of an intangible asset comprises its purchase price, including any import duties and other taxes (other than those subsequently recoverable from the taxing authorities), and any directly attributable expenditure on making the asset ready for its intended use. Expenditure on Research and development eligible for capitalisation are carried as Intangible assets under development where such assets are not yet ready for their intended use.

**d Depreciation and amortization**

Depreciation on tangible assets is provided on straight line method and in the manner prescribed in Schedule II to the Companies Act, 2013, over its useful life specified in the Act, or based on the useful life of the assets as estimated by Management based on technical evaluation and advice. The residual value is 5% of the acquisition cost which is considered to be the amount recoverable at the end of the asset's useful life. The residual values, useful lives and method of depreciation of property, plant and equipment is reviewed at each financial year end.

**e Investments**

Current investments are carried at lower of cost or quoted / fair value, computed category wise. Long term investments are stated at cost. Provision for diminution in value of long term investments is made only if such decline is other than temporary in the opinion of the management.

**f Borrowing costs**

Borrowing cost that is attributable to the acquisition or construction of qualifying asset are capitalized as part of the cost of such assets. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use. All other borrowing costs are charged to revenue.

**g Provision for Current Tax & Deferred Tax**

Provision for current tax is made after taking into considerations benefits admissible under the provisions of The Income Tax Act, 1961. Deferred Tax resulting from the timing differences between the taxable and accounting income is accounted for using the tax rates and laws that are enacted or substantively enacted as on balance sheet date. The deferred tax asset is recognized and carried forward only to the extent that there is reasonable/virtual certainty that the asset will be realized in future.

**h Provision for Contingent Liabilities and Contingent Assets**

Provisions involving substantial degree of estimation in measurement are recognized when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources. Contingent liabilities are not recognized but are disclosed in the Notes. Contingent Assets are neither recognized nor disclosed in the financial statements.

**i Earnings per share**

Basic earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year adjusted for the effects of all dilutive potential equity shares.

**j Foreign Currency Transactions**

i) Transactions denominated in foreign currencies are recorded at exchange rate prevailing on the date of transaction for Sales and Custom rates for Purchases as on date of the transaction.

ii) Monetary items denominated in foreign currencies at the year end are restated at year end rates

iii) Non-monetary foreign currency items are carried at cost.

iv) Any income or expense on account of exchange difference either on settlement or on translation is recognized as revenue except in cases where they relate to acquisition of fixed assets in which case they are adjusted to the carrying cost of such asset.

**k Inventories**

Inventories of finished goods, raw materials, and work in progress are carried at lower of cost or net realisable value. The cost of inventories of items that are not ordinarily interchangeable are assigned by specific identification of their individual costs. Other inventory items are recorded using first-in-first-out cost formula. The inventories include the relevant duties, taxes, and cess other than those subsequently recoverable by the enterprise from the taxing authorities that were incurred to bring the inventory to their present location and conditions.

**l Cash Flow Statement**

Cash flows are reported using the indirect method, whereby the net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of the past or future cash receipts or payments. The cash flows from regular revenue generating, investing & financing activities of the company are segregated.

**m Revenue Recognition**

Sales turnover for the year includes sales value of goods and other recoveries such as Octroi, Transportation Charges etc, but excludes Excise duty and GST. Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue from sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer. Export incentives are recognized when it is probable to receive such benefits. Revenue from sale of scrap and licences are recognized as and when they are sold. Interest income from financial assets is recognized on accrual basis.

**n Retirement Benefits**

The Company's contribution to Provident Fund and ESIC is accounted on accrual basis and charged to Profit and Loss Account. The Company accounts for liability for Gratuity of employees on the basis of Actuarial Valuation/Management Estimates. Gratuity is payable to Employees after Retirement or Resignation of Employees; whereas there is no defined policy enabling the employees to avail encashment of leave.

**o Impairment of Assets**

An asset is treated as impaired when the carrying cost of the Asset exceeds its recoverable value. An impairment loss is charged to the Profit & Loss account in the year in which an asset is identified as impaired. The Impairment loss recognized in prior accounting periods is increased / reversed where there has been change in the estimate of recoverable amount. The recoverable value is the higher of the net selling price and value in use.

**p Leases**

Assets leased by the Company in its capacity as lessee, where the Company has substantially all the risks and rewards of ownership are classified as finance lease. Such a lease is capitalized at the inception of the lease at lower of the fair value or the present value of the minimum lease payments and a liability is recognized for an equivalent amount. Each lease rental paid is allocated between the liability and the interest cost so as to obtain a constant periodic rate of interest on the outstanding liability for each year. Lease arrangements where the risks and rewards incidental to ownership of an asset substantially vest with the lessor, are recognized as operating leases. Lease rentals under operating leases are recognized in the statement of profit and loss on a straight-line basis.

**q Cash and Cash Equivalents**

Cash and cash equivalents comprise cash on hand and demand deposits, together with other short-term, highly liquid investments maturing within 3 months from the date of acquisition that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value.

**r Financial Assets and Financial Liabilities**

Financial assets (other than trade receivables) and financial liabilities are recognized when the Company becomes a party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted for transaction costs, except for those carried at fair value through profit and loss which are measured initially at fair value.

Trade receivables are recognized at their transaction price as the same do not contain significant financing component.

For the purpose of subsequent measurement financial assets and financial liabilities are classified and measured based on the entity's business model for managing the financial asset and the contractual cash flow characteristics of the financial asset and the financial liability.

### Note 3

## PROPERTY, PLANT AND EQUIPMENT

[illegible]



**Note 4 FINANCIAL ASSETS - LOANS (NON-CURRENT)**

Particulars	31 March 2021		31 March 2020	
	Rs.	Rs.	Rs.	Rs.
Loans and advances to related parties		-		-
Other loans and advances (Unsecured, considered good)	-			
- Staff Loans		2,046,500		1,687,000
<b>Total</b>		2,046,500		1,687,000

**Note 5 OTHER NON CURRENT ASSETS**

Particulars	31 March 2021		31 March 2020	
	Rs.	Rs.	Rs.	Rs.
Security Deposits (Unsecured, considered good)				
- Deposits with various authorities		4,114,647		2,044,029
Provident Fund Refund		120,652		-
Receivable				-
Tds Credit Receivable (Igst 2%)		120,505		-
Tds Exces Payment		1,800		-
Income tax refund receivable		-		-
Income tax deposited under appeal		288,516		288,516
Debts due by related parties		-		-
Un-amortized Employee Cost		-		-
<b>Total</b>		4,646,120		2,332,545

**Note 6 INVENTORIES**

Sr. No.	Particulars	31 March 2021		31 March 2020	
		Rs.	Rs.	Rs.	Rs.
a.	Raw Materials and components (Valued at lower of cost or net realisable value)	25,733,063		77,697,229	
	Traded goods	-		-	
	Goods-in transit	-	25,733,063	-	77,697,229
b.	Work-in-progress (Valued at lower of cost or net realisable value)	781,017		905,883	
	Goods-in transit	-	781,017	-	905,883
c.	Finished goods (Valued at lower of cost or net realisable value)	86,501,089		108,651,301	
	Goods-in transit	-	86,501,089	-	108,651,301
d.	Stores and spares (Valued at lower of cost or net realisable value)	-		-	
	Goods-in transit	-	-	-	-
e.	Loose Tools (Valued at Not Applicable)	-		-	
	Goods-in transit	-	-	-	-
f.	Packing Material (Valued at lower of cost or net realisable value)	983,489		419,174	
	Goods-in transit	-	983,489	-	419,174
	<b>Total Inventories</b>		<b>113,998,658</b>		<b>187,673,586</b>

**Note 7 CURRENT INVESTMENTS**

Disclosure pursuant to Note no.N (i) and (ii) of Part I of Schedule III to the Companies Act, 2013

Particulars	31-03-2021	31-03-2020
	Rs.	Rs.
(a) Investment in Equity instruments	-	-
(b) Investments in preference shares	-	-
(c) Investments in Government or Trust securities	-	-
(d) Investments in Debentures or Bonds	-	-
(e) Investments in Mutual Funds	10,000	10,000
(f) Investments in partnership firms*	-	-
(g) Other non-current investments (specify nature)	-	-
<b>Gross Total</b>	<b>10,000</b>	<b>10,000</b>
<u>Less:</u> Provision for diminution in the value of Investments	-	-
<b>Total Current Investments</b>	<b>10,000</b>	<b>10,000</b>

Particulars	31-03-2021	31-03-2020
	Rs.	Rs.
Aggregate amount of quoted investments (Market value Rs. 14642.89) (Previous Year Rs. 11,469.20)	10,000	10,000
Aggregate amount of unquoted investments (Previous Year Rs. __)	-	-

Details of Current Investments											
Sr. No	Name of the Body Corporate	Subsidiary / Associate / JV/ Controlled Entity / Others	No. of Shares / Units		Quoted / Unquoted	Partly Paid / Fully paid	Extent of Holding (%)		Amount (Rs.)		Basis of Valuation
			31-03-2021	31-03-2020			31-03-2021	31-03-2020	31-03-2021	31-03-2020	
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)
(a)	Investment in Equity Instruments										
(b)	Investments in Preference Shares										
(c)	Investments in Government or Trust securities										
(d)	Investments in Debentures or Bonds										
(e)	Investments in Mutual Funds		48.05	48.05	Quoted	Fully paid			10,000	10,000	Cost
(f)	Investments in partnership firms*										
(g)	Other non-current investments (specify nature)										
	<b>Total Current Investments</b>								<b>10,000</b>	<b>10,000.00</b>	

* <b>G. Investment in NOT APPLICABLE (Name of the Firm)</b>	
Name of the Partners	Share of Capital
Partner 1	-
Partner 2	-
<b>Total Capital</b>	<b>-</b>

**Note 8 TRADE RECEIVABLES**

Particulars	31/03/21	31/03/20
	Rs.	Rs.
Dues from Related parties	-	-
Dues from Others		
- Secured, considered good	-	-
- Unsecured, considered good	330,054,234	278,128,141
- Unsecured, considered doubtful	-	2,288,000
	330,054,234	280,416,141
Less: Provision for doubtful debts	-	2,288,000
	-	-
<b>Total</b>	<b>330,054,234</b>	<b>278,128,141</b>

**Note 9 CASH AND CASH EQUIVALENTS**

Particulars	31 March 2021		31 March 2020	
	Rs.	Rs.	Rs.	Rs.
Balances with banks		2,374,146		2,146,538
Cash on hand		411,420		427,283
Fixed deposit with banks (Maturity with more than 12 months)		22,640,000		9,144,800
	-	-	-	-
<b>Total</b>		<b>25,425,565</b>		<b>11,718,621</b>

**Note 10 FINANCIAL ASSET - LOANS (CURRENT)**

Particulars	31 March 2021		31 March 2020	
	Rs.	Rs.	Rs.	Rs.
Related parties		-		-
Others				
- Secured, considered good		-		-
- Unsecured, considered good		180,000		234,000
(Current portion of Staff Loans)				
Sundry Creditors For Fixed Assets		-		-
Considered Doubtful	-	-	-	-
Less: Provision for doubtful	-	-	-	-
<b>Total</b>		<b>180,000</b>		<b>234,000</b>

**Note 11 OTHER FINANCIAL ASSETS (CURRENT)**

Particulars	31 March 2021		31 March 2020	
	Rs.	Rs.	Rs.	Rs.
Forward contract value		-		-
<b>Total</b>		-		-

**Note 12 OTHER CURRENT ASSETS**

Particulars	31 March 2021		31 March 2020	
	Rs.	Rs.	Rs.	Rs.
<b><u>Related to Income Tax</u></b>		-		-
<b><u>Others</u></b>				
Gst Credit / Refund Receivable	-		5,053,554	
Cenvat / Gst / Customs Credit Balance	-		-	
Bank Fdr Accrued Interest	222,652		106,670	
Travel Card	-		351,668	
Export Incentive Receivable	2,952,482		1,516,097	
Advances Given	168,674		10,785,561	
Prepaid Expenses	226,183		1,226,931	
		3,569,991		19,040,482
<b>Total</b>		3,569,991		19,040,482

**Note 13 SHARE CAPITAL**

<b>a</b>	<b>Share Capital</b>	31 March 2021		31 March 2020	
		Number	Rs.	Number	Rs.
	<b><u>Authorised</u></b>				
	Equity Shares of Rs. 10 each	5,000,000	50,000,000	5,000,000	50,000,000
	<b><u>Issued</u></b>				
	Equity Shares of Rs. 10 each	3,089,700	30,897,000	3,089,700	30,897,000
	<b><u>Subscribed &amp; Paid up</u></b>				
	Equity Shares of Rs. 10 each fully paid	3,089,700	30,897,000	3,089,700	30,897,000
	<b><u>Subscribed but not fully Paid up</u></b>				
	Equity Shares of Rs. 10 each, not fully paid up	-	-	-	-
	<b>Total</b>	3,089,700	30,897,000	3,089,700	30,897,000

**b Reconciliation of number of shares outstanding is set-out below**

Particulars - Equity Shares	31 March 2021		31 March 2020	
	Number	Rs.	Number	Rs.
Shares outstanding at the beginning of the year	3,089,700	30,897,000	3,089,700	30,897,000
Shares Issued during the year	-	-	-	-
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	3,089,700	30,897,000	3,089,700	30,897,000

**c Shareholders holding more than 5% of the aggregate shares in the Company**

Name of Shareholder	31 March 2021		31 March 2020	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
Lalit Mehta	431,498	13.97%	431,498	13.97%
Rajesh Mehta	381,042	12.33%	381,042	12.33%
Premal Mehta	175,281	5.67%	175,281	5.67%
Mala Bhavnani	188,706	6.11%	188,706	6.11%

- d** There were no shares issued pursuant to contract without payment being received in cash, allotted as fully paid up by way of bonus issues and there were no buy back of shares during the last 5 years immediately preceding 31-Mar-2021

**e Terms/ rights attached to equity shares**

The Company has equity shares having a par value of Rs. 10. Each holder of equity shares is entitled to one vote per share.

**Note 14 OTHER EQUITY**

Particulars	31/03/2021	31/03/2020
	Rs.	Rs.
<b>Surplus</b>		
Opening balance	212,139,743	169,772,239
(+) Net Profit/(Net Loss) for the current year	53,331,789	42,367,504
(+) Transfer from Reserves	-	-
(-) Proposed Dividends	-	-
(-) Interim Dividends	-	-
(-) Transfer to Reserves	-	-
Closing Balance	<b>265,471,531</b>	<b>212,139,743</b>
<b>Total</b>	<b>265,471,531</b>	<b>212,139,743</b>

**Note 15 BORROWINGS**

Particulars	31/03/2021	31/03/2020
	Rs.	Rs.
<b><u>Secured</u></b> <b>Term loans</b>	-	-
<b>Total</b>	-	-

**Note 16 DEFERRED TAX LIABILITY (NET)**

The Company has accounted for taxes on income in accordance with IND AS 12 – Income Tax issued by the Ministry of Corporate Affairs. Consequently, the net incremental deferred tax (liability) / asset is charged / credited to Profit and Loss Account. The year end position of taxes on income is as under:

Particulars	31/03/2021	31/03/2020
	Rs.	Rs.
<b>Deferred tax liability</b>		
Fixed Assets : Impact of Difference between tax depreciation and depreciation / amortisation charged for financial reporting	5,299,080	4,732,812
Others	-	-
Gross deferred tax liability	5,299,080	4,732,812
<b>Deferred tax asset</b>		
Impact of expenditure charged to the statement of profit and loss in the current year but allowed for tax purposes on payment basis	-	-
Unabsorbed Depreciation as per Tax	-	-
Difference in stock value as per accounts and as per tax	973,499	2,492,140
Reserve for doubtful debts	-	575,844
Gratuity liability (not paid)	-	216,949
Gross deferred tax asset	973,499	3,284,933
<b>Net deferred tax liability / (asset)</b>	<b>4,325,581</b>	<b>1,447,879</b>

**Note 17 OTHER FINANCIAL LIABILITIES**

Particulars	31/03/2021	31/03/2020
	Rs.	Rs.
Refund of Income Tax under appeal	0	0
<b>Total</b>	<b>0</b>	<b>0</b>



**Note 18 BORROWINGS - CURRENT**

Particulars	31/03/2021	31/03/2020
	Rs.	Rs.
<b><u>Secured</u></b>		
<b>Other loans and advances</b>		
<b>Cash Credit from ICICI bank</b>	87,936,611	90,966,870
(Secured by hypothecation of Stock, Book Debts, and first charge over Fixed Assets. As a collateral security, the promoter directors Mr. Lalit Mehta and Mr. Rajesh Mehta have given their personal guarantee)		
Period of Maturity	Cash Credit Account	
Number and amount of Instalments due	Not Applicable	
Rate of Interest	11.05%	
Other significant terms	-	
<b>Total</b>	<b>87,936,611</b>	<b>90,966,870</b>

**Note 19 TRADE PAYABLES**

Particulars	31/03/2021	31/03/2020
	Rs.	Rs.
(a) Sundry Creditors For Goods	176,488,713	227,434,134
(b) Sundry Creditors For Expenses	113,524	4,027,143
<b>Total Trade Payables</b>	<b>176,602,236</b>	<b>231,461,278</b>

The Ministry of Micro, Small and Medium Enterprises has issued an office memorandum dated August 26, 2008, which recommends that the Micro and Small Enterprises should mention in their correspondence with its customers the Entrepreneurs Memorandum Number as allocated after filing of the Memorandum in accordance with the 'Micro, Small and Medium Enterprises Development Act, 2006' ('the Act'). There are no dues to enterprises which have provided goods and services to the Company and which qualify under the definition of micro and small enterprises, as defined under Micro, Small and Medium Enterprises Development Act, 2006 as at 31-Mar-2021 and 31-Mar-2020 respectively based on the information received and available with the Company.

Particulars	31/03/2021	31/03/2020
	Rs.	Rs.
The principal amount and the interest due thereon remaining unpaid to any supplier as at the end of each accounting year.	-	-
The amount of interest paid by the Company along with the amounts of the payment made to the supplier beyond the appointed day during the year;	-	-
The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under this Act;	-	-
The amount of interest accrued and remaining unpaid at the end of the year	-	-
The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise.	-	-

**Note 20 OTHER CURRENT LIABILITIES**

Particulars	31/03/2021	31/03/2020
	Rs.	Rs.
(a) Current maturities of long-term debt	-	3,120,998
(b) Current maturities of finance lease obligations	-	-
(c ) Interest accrued but not due on borrowings	-	20,605
(d) Interest accrued and due on borrowings	-	-
(e) Income received in advance	-	-
(f) Unpaid dividends	-	-
(g) Application money received for allotment of securities and due for refund	-	-
interest accrued on (g) above	-	-
(h) Unpaid matured deposits and interest accrued thereon	-	-
(i) Unpaid matured debentures and interest accrued thereon	-	-
(j) Other payables (specify nature)		
- Sundry Creditors For Fixed Assets	-	-
- Tcs Credit Received (Person Not Known)	1,316	-
- Advances Received Against Order/Goods	-	-
- Liability Towards Group Gratuity	-	862,004
- Gst Payable	1,446,616	27,912
- Notional Excise Liability On Finished Goods	-	-
- Deferred Gain On Forward Contract	-	-
- Tds / Tcs Payable	260,880	357,753
<b>Total</b>	<b>1,708,812</b>	<b>4,389,273</b>

**Note 21 PROVISIONS - CURRENT**

Particulars	31/03/2021	31/03/2020
	Rs.	Rs.
<b>(a) Provision for employee benefits</b>		
Salary & Reimbursements	-	-
Provision For Employee Benefits (Pf, Esic)	121,406	123,619
<b>(b) Others (Specify nature)</b>		
Provision For Audit Fees	155,000	-
Provision for Taxation	6,746,487	12,060,314
<b>Total</b>	<b>7,022,893</b>	<b>12,183,933</b>

**Note 22 REVENUE FROM OPERATIONS**

Particulars	31 March 2021		31 March 2020	
	Rs.	Rs.	Rs.	Rs.
Sale of products	2,043,286,997		1,570,675,371	
Sale of services	-		-	
Other operating revenues	-		-	
Foreign Exchange Fluctuation	409,856		491,095	
<b>Gross Revenue</b>		2,043,696,853		1,571,166,466
<b>Less:</b>		-		
Excise duty	-		-	
GST	253,519,024		196,641,709	
Sales tax	-	253,519,024	-	196,641,709
<b>Net Revenue From Operations</b>		<b>1,790,177,828</b>		<b>1,374,524,757</b>

**Note 23 OTHER INCOME**

Particulars	31 March 2021		31 March 2020	
	Rs.	Rs.	Rs.	Rs.
Interest Income (in case of a company other than a finance company)				
Fdr & Other Interest Received	770,575		693,848	
Interest on Staff Loans	-		-	
Interest on Deposits	83,991		269,326	
Insurance Claim Income	12,125		-	
Reserve for Doubtful Debts reversed	2,270,300	3,136,991	-	963,174
Export Incentives	1,491,143		750,182	
Income From Sale Of Scrap - Shown Under Sales	-		11,000	
Licences Sale	-	1,491,143	3,997,153	4,758,335
Net gain / (loss) on sale of investments		-		-
<b>Total</b>		<b>4,628,134</b>		<b>5,721,509</b>

**Note 24 COST OF MATERIAL CONSUMED**

Particulars	31 March 2021		31 March 2020	
	Rs.	Rs.	Rs.	Rs.
<u>Materials Consumed</u>				
<u>Opening Stock</u>				
Raw Materials	77,697,229		31,134,538	
Packing Materials	419,174		410,312	
Consumables including Spare Parts	-			
		<b>78,116,403</b>		<b>31,544,850</b>
Add : Cost of Purchases		1,568,776,129		1,364,551,907
<u>Less : Closing Stock</u>				
Raw Materials	25,733,063		77,697,229	
Packing Materials	983,489		419,174	
Consumables including Spare Parts	-		-	
		<b>26,716,552</b>		<b>78,116,403</b>
<b>Cost of Material consumed</b>		<b>1,620,175,980</b>		<b>1,317,980,354</b>

**Note 25 (INCREASE) / DECREASE IN INVENTORIES**

Particulars	31 March 2021		31 March 2020	
	Rs.	Rs.	Rs.	Rs.
<b>Inventories at the end of the year</b>				
Work-in-progress	781,017		905,883	
Finished Goods	86,501,089		108,651,301	
Traded Goods	-	87,282,106	-	109,557,183
<b>Inventories at the beginning of the year</b>				
Work-in-progress	905,883		699,551	
Finished Goods	108,651,301		47,051,985	
Traded Goods	-	109,557,183	-	47,751,537
<b>Net (Increase) / Decrease in Inventories</b>		<b>22,275,077</b>		<b>-61,805,647</b>

**Note 26 EMPLOYEE BENEFIT EXPENSES**

Particulars	31 March 2021		31 March 2020	
	Rs.	Rs.	Rs.	Rs.
(a) Salaries, Wages and bonus				
Other Employees		7,090,828		7,267,693
Directors' Remuneration		4,440,000		4,440,000
(b) Contributions to -				
Provident fund	705,601		727,643	
Employee State Insurance Corporation	89,816		107,521	
Employee Insurance	-		2,447	
(c) Gratuity fund contributions	1,727,730		862,004	
(d) Social security and other benefit plans for overseas employees	-		-	
(e) Expense on Employee Stock Option Scheme (ESOP) and Employee Stock Purchase Plan (ESPP)	-		-	
(f) Staff welfare expenses	926,276	3,449,423	1,032,052	2,731,667
<b>Total</b>		<b>14,980,251</b>		<b>14,439,360</b>

**Note 27 FINANCE COST**

Particulars	31 March 2021		31 March 2020	
	Rs.	Rs.	Rs.	Rs.
<b><u>Interest Charges</u></b>				
Interest on Term Loan	37,711		568,021	
Interest on other borrowings	9,333,051	9,370,762	6,730,090	7,298,111
<b><u>Other borrowing costs</u></b>				
Bank Charges and commission incl L/c, others	3,395,966		2,485,210	
Car hire Purchase Finance charges	-	3,395,966	-	2,485,210
<b>Total</b>		<b>12,766,728</b>		<b>9,783,321</b>

## Note 28 OTHER EXPENSES

Particulars	31 March 2021		31 March 2020	
	Rs.	Rs.	Rs.	Rs.
<b>1. Manufacturing Expenses</b>				
Contract Labour	6,817,192		6,679,864	
Job Work Charges	-		-	
Power Charges	2,971,643		2,674,518	
Fuel Consumed	300,477		339,870	
Gas Charges	7,361,329		5,760,478	
Water & Drainage Charges	468,104		242,872	
Analytical & Testing Charges	957,196		1,133,328	
Insurance Charges	402,334		499,772	
Notional Excise On Stock Of Finished Goods	-		-	
Repairs To Factory Building	1,698,876		151,012	
Repairs To Plant & Machinery	6,127,422		2,768,383	
Effluent Treatment & Pollution Control	1,486,378		961,105	
Other Manufacturing Expenses	58,900		1,154,493	
		<b>28,649,851</b>		<b>22,365,695</b>
<b>2. Other Expenses :</b>				
Directors' Sitting Fees	285,000		240,000	
Office Electricity	83,521		120,500	
Society Maintenance Charges	296,670		159,992	
Rates & Taxes	366,171		755,713	
Profession Tax	2,400		-	
Legal & Professional Charges	1,771,920		1,061,638	
Printing, Stationery & Periodicals	801,557		774,936	
Conveyance - Local	292,070		356,500	
Vehicle Expenses	110,535		128,466	
Travelling - Outdoor	28,741		145,924	
Telephone, Internet & Communication Expenses	297,456		331,634	
Postage & Courier Charges	58,290		241,741	
Auditor'S Remuneration	257,500		340,000	
Stock Exchange, Mca & Custodial Fees	464,849		388,974	
Software And Hardware Maintenance	315,390		318,992	
Office Maintenance, Repairs & Renewals	307,191		274,857	
Insurance	35,706		24,909	
Advertisement (Statutory)	48,128		42,864	
Security Charges	373,384		370,802	
Stipend	6,600		66,112	
C.S.R. Expenses	840,883		-	
Sundry Expenses	134,645		146,404	
Donation	65,000		118,500	
		<b>7,243,607</b>		<b>6,409,457</b>

Export Expenses	931		81,479	
Clearing & Forwarding	2,494,190		983,322	
Advertisement & Publicity	375,388		152,223	
Business Promotion	371,002		441,949	
Bad Debts Written Off	2,270,300		-	
Reserve For Doubtful Debts	-		689,700	
Discount	-14,038		-43,003	
Commission & Brokerage	3,211,558		4,391,084	
Gst / Sales Tax	-		10,681	
Insurance - Goods-In-Transit (Sales)	364,001		-	
Travelling - Foreign	-157,000		846,800	
Delivery Charges	1,253,729		1,286,847	
		10,170,061		8,841,082
<b>Total</b>		<b>46,063,519</b>		<b>37,616,235</b>

## NOTES TO THE FINANCIAL STATEMENTS

- 29** The value on realization of current assets in the ordinary course of business would not be less than the amount at which they are stated in the Balance Sheet. According to the management, provision for all the known liabilities is adequate.
- 30** Balances in Debtors, Creditors, loans, advances, and other current assets are subject to confirmation and reconciliation.
- 31** Auditors' remuneration in accordance with paragraph 4B of part II of Schedule III to the Companies Act 2013 is as under:

Particulars	31 March 2021	31 March 2020
As Statutory Auditors	120,000	215,000
As Tax Auditors	50,000	50,000
As VAT Auditors	75,000	75,000
As Cost Auditors	-	-
As Secretarial Auditors	-	-
Company Law Matters	-	-
Management Services	-	-
Other Services	12,500	-
Reimbursement of expenses	-	-
	<b>257,500</b>	<b>340,000</b>

**32 Earnings per share is calculated as under:**

Particulars	31 March 2021	31 March 2020
<b>Basic earning per share</b>		
Net profit after Taxation	53,331,789	42,367,504
Number of shares issued (Nominal Value Rs.10)	3,089,700	3,089,700
Basic earning per share	17.26	13.71
<b>Diluted earning per share</b>		
Net profit after Taxation	53,331,789	42,367,504
Number of shares issued (Nominal Value Rs.10)	3,089,700	3,089,700
Diluted earning per share	17.26	13.71

**33 Directors' Remuneration**

Particulars	31 March 2021	31 March 2020
Within the limits of Schedule V to the Companies Act 2013.	4,440,000	4,440,000

**34 Disclosure of Provisions as required by Ind AS-12 is as under:**

Particulars	Opening Balance	Additional provisions during the year	Amount Used & Unused amount reversed during the year	Closing Balance
		Rs.	Rs.	Rs.
Income tax provision	12,060,314	17,204,493	22,518,320	6,746,487

**35 Related Party Disclosures, as required by Ind AS-24 are given below:**

The company has the following related parties :

- a) Holding Company  
Nil
- b) Fellow Subsidiaries with whom transactions have taken place  
Nil
- c) Enterprise where Key Mannegerial Personnel has Significant Influence  
Nil
- d) Key Management Personnel  
Mr. Lalit Mehta  
Mr. Rajesh Mehta  
Mr. Megh Mehta
- e) Entity that has significant influence  
Nil
- f) Transaction with related parties for the year ended 31 March 2021



Sr. No.	Transaction	Enterprise where Key Managerial Personnel has Significant Influence	Key management personnel	Entity that has significant influence	Total
1	Issue of Shares	-	-	-	-
2	Expenses incurred	-	-	-	-
3	Expenses incurred on behalf of	-	-	-	-
4	Interest on unsecured loan	-	-	-	-
5	Interest received on unsecured loan	-	-	-	-
6	Unsecured loan paid to	-	-	-	-
7	Unsecured loan received from	-	-	-	-
8	Repayment of loan to	-	-	-	-
9	Managerial remuneration & Incentive	-	4,440,000	-	4,440,000

g) Transaction with related parties for the year ended 31 March 2020

Sr. No.	Transaction	Enterprise where Key Managerial Personnel has Significant Influence	Key management personnel	Entity that has significant influence	Total
1	Issue of Shares	-	-	-	-
2	Expenses incurred	-	-	-	-
3	Expenses incurred on behalf of	-	-	-	-
4	Interest on unsecured loan	-	-	-	-
5	Interest received on unsecured loan	-	-	-	-
6	Unsecured loan paid to	-	-	-	-
7	Unsecured loan received from	-	-	-	-
8	Repayment of loan to	-	-	-	-
9	Managerial remuneration & Incentive	-	4,440,000	-	4,440,000

h) The balances receivable from and payable to related parties as at 31 March 2021

Sr. No.	Transaction	Enterprise where Key Mannegerial Personnel has Significant Influence	Key management personnel	Entity that has significant influence	Total
1	Unsecured loan payable	-	-	-	-
2	Expense Payable	-	-	-	-
3	Rent Payable	-	-	-	-

i) The balances receivable from and payable to related parties as at 31 March 2020

Sr. No.	Transaction	Enterprise where Key Mannegerial Personnel has Significant Influence	Key management personnel	Entity that has significant influence	Total
1	Unsecured loan payable	-	-	-	-
2	Expense Payable	-	-	-	-
3	Rent Payable	-	-	-	-

**36** Value of imports calculated on C.I.F basis by the company during the financial year in respect of:

Particulars	31 March 2021	31 March 2020
i Raw materials	1,334,152,736	1,115,437,893
ii Components and spare parts	-	-
iii Capital goods	-	-
iv Trading Goods	-	-

**37** Other Expenses in Foreign Currency:

Particulars	31 March 2021	31 March 2020
i Royalty, Know-how, Professional and Consultation fees, Interest, and Other matters	-	88,684
ii Total value of all imported / indigenous raw materials, spare parts and components consumed and the percentage of each to the total consumption	-	-
iii Amount remitted in foreign currencies on account of dividends with a specific mention of the total number of non-resident shareholders, the total number of shares held by them on which the dividends were due and the year to which the dividends related;	-	-
iv Earnings in foreign exchange classified under the following heads, namely	-	-
i Export of goods calculated on F.O.B. basis	136,618,823	69,278,295
ii Royalty, know-how ,professional and consultation fees;	-	-
iii Interest and dividend	-	-
iv Other income, indicating the nature thereof	-	-

	-	-
--	---	---

**38 Information of major Raw Material Consumption**

Particulars	31 March 2021		31 March 2020	
	Quantity	Rupees	Quantity	Rupees
Iodine Crude	504.77 MT	1,379,852,854	460.77 MT	1,080,801,587
<b>Grand Total</b>	504.77 MT	1,379,852,854	460.77 MT	1,080,801,587

**39** The turnover is shown net of all indirect taxes viz. GST.

**40** The disclosure of “Employee Benefits” as per Ind AS-19 are as follows:

**(A) Defined contribution plans:****Provident fund, ESIC:**

The Company has recognized the following amounts in the Profit and Loss Account for the year:

(i) Contribution to Provident Fund (Employer's Contribution) Rs. 7,05,601

(ii) Contribution to ESIC (Employer's Contribution) Rs. 89,816

(B) Defined Benefit Plans

**(i) Disclosure of Gratuity Liabilities**

The Company has taken a group gratuity policy with LIC to cover its gratuity liabilities

**41** Since the company has only one primary product line and its operations are restricted to only one geographical area, the financial statements itself may be considered to be the segment results as per the disclosure requirements of Ind AS-108

**42 Contingent Liabilities and Commitments**

Particulars	31/03/2021	31/03/2020
<b>Claims against the company not acknowledged as debt</b>		
a. Income tax assessment dues for AY 2011-12 under appeal pending before first appellate authority	-	-
b. Income tax assessment dues for AY 2011-12 under appeal pending before first appellate authority (Interest Income)	715,740	715,740

**43** The management has made full inquiries and is of the view that assets of the Company in form of fixed assets and Inventories are good in nature, and are stated at appropriate value of the respective assets; and there is no necessity as to impairment / write down provision in the accounts.

**44** Disclosures required under Ind AS-17 on “Leases”

**Finance Lease - Assets Given on Lease**

The Company has not given any of its assets on lease.

<b>Operating Lease - Assets Taken on Lease</b>	<b>31/03/2021</b>	<b>31/03/2020</b>
Total of future minimum lease payments under non-cancellable operating leases for each of the following periods:	-	-
- Not later than one year,	-	-
- Later than one year and not later than five years;	-	-
- Later than five years;	-	-
Total of future minimum sublease payments expected to be received under non-cancellable subleases at the balance sheet date	-	-
Lease payments recognized in the statement of profit and loss for the period, with separate amounts for minimum lease payments and contingent rents	-	-
sub-lease payments received (or receivable) recognized in the statement of profit and loss for the period	0	0
General description of the lessee's significant leasing arrangements including, but not limited to, the following: Basis on which contingent rent payments are determined; Existence and terms of renewal or purchase options and escalation clauses; and Restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing.	Not Applicable	Not Applicable

<b>Operating Lease - Assets Given on Lease</b>	<b>31/03/2021</b>	<b>31/03/2020</b>
Gross carrying amount	-	-
Accumulated depreciation	-	-
Accumulated impairment losses	-	-
the depreciation recognized in the statement of profit and loss for the period	-	-
Impairment losses recognized in the statement of profit and loss for the period	-	-
impairment losses reversed in the statement of profit and loss for the period;	-	-
Future minimum lease payments under non-cancellable operating leases in the aggregate and for each of the following periods	-	-
Not later than one year;	-	-
Later than one year and not later than five years;	-	-
Later than five years;	-	-
Total contingent rents recognized as income in the statement of profit and loss for the period	-	-

- 45 The Company has a process whereby periodically all long term contracts are assessed for material foreseeable losses. At the year end, the Company has reviewed and ensured that adequate provision as required under any law / accounting standards for material foreseeable losses on such long term contracts has been made in the books of account.
- 46 The Company has a system of reviewing its pending litigations and proceedings, if any, and provide for where Provisions are required and disclose the contingent liabilities where applicable, in its financial statements. The Company does not expect the outcome of these proceedings to have a materially adverse effect on its financial results. In respect of litigations, where the management assessment of a financial outflow is probable, the Company has made adequate provision in the financial statements and the contingent liabilities are disclosed in Note 42.
- 47 Current assets, Loans & Advances have a value of realisation in the ordinary course of business at least equal to the amount at which they are stated.
- 48 Previous year figures have been re-grouped & re-arranged wherever necessary.

**AS PER OUR REPORT OF EVEN DATE**

For Shah & Savla LLP  
Chartered Accountants

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS  
For Samrat Pharmachem Limited

Miral H. Nagda  
Partner  
Membership No.: 108135  
FRN: 109364W / W100143  
Place : Mumbai  
Date : 30 June 2021

Lalit Mehta  
Managing Director  
[DIN: 00216681]  
  
Mahendra Pipalia  
Director  
[DIN: 00216959]

Rajesh Mehta  
Executive Director  
[DIN: 00216731]  
  
Samir Kothary  
Director  
[DIN: 00216603]

Megh Mehta  
Executive Director  
[DIN: 07287394]  
  
Renu Dharod  
Director  
[DIN: 07063088]

**CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH, 2021**

Particulars	31-Mar-21 Rs. Lakhs	31-Mar-20 Rs. Lakhs
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Profit Before Tax And Extraordinary Items	734.39	578.50
Adjustments For :		
Depreciation	49.29	42.63
Profit/Loss On Sale Of Assets	1.77	1.20
Profit/Loss On Sale Of Investments	0.00	0.00
Finance Cost	127.67	97.83
Bad Debts, Reserve For Doubtful Debts & Discount	-0.14	6.47
Interest/Dividend Income	-8.55	-9.63
	170.04	138.50
Operating Profit Before Working Capital Changes	904.43	716.99
Adjustments For :		
Trade Receivables	-519.26	-676.49
Other Receivables	129.81	-35.05
Inventories	736.75	-1,083.77
Trade And Other Payables	-542.86	1,033.19
	-195.56	-762.12
Cash Generated From Operations	708.86	-45.12
Direct Taxes Paid	-225.43	-87.41
	-225.43	-87.41
Cash Flow Before Extraordinary Items	483.43	-132.54
Extraordinary Items		
Net Cash From Operating Activities	483.43	-132.54
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase Of Fixed Assets	-272.86	-76.16
Sale/Realization Of Fixed Assets	0.00	0.10
Capital Work-In-Progress	108.08	-108.08
Addition/Realization Of Investments/FDR	-134.95	-17.10
Interest/Dividend Received	7.39	9.08
Net Cash Used In Investing Activities	-292.34	-192.17

	Continued ...	
Particulars	31-Mar-21 Rs. Lakhs	31-Mar-20 Rs. Lakhs
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds From Issue Of Share Capital	0.00	0.00
Interest & Finance Charges Paid	-127.46	-87.43
Proceeds/Repayment - Long Term Borrowings	-31.21	-44.91
Proceeds/Repayment - Short Term Borrowings	-30.30	332.51
Net Cash Used In Financing Activities	-188.97	200.17
 NET INCREASE IN CASH AND CASH EQUIVALENTS	 2.12	 -124.54
CASH AND CASH EQUIVALENTS AT (Opening Balance) 1/Apr	25.74	150.27
CASH AND CASH EQUIVALENTS AT (Closing Balance) 31/Mar	27.86	25.74

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS  
**For Samrat Pharmachem Limited**

**Rajesh Mehta**  
**Executive Director**  
[DIN: 00216731]

Place : Mumbai  
Date : 30 June 2021



# AatmaNirbharBharat Abhiyan

When India speaks of becoming self-reliant, it doesn't advocate a self-centred system. In India's self-reliance; there is a concern for the whole world's happiness, cooperation and peace.

Hon'ble Prime Minister, **Shri Narendra Modi**



**Book-Post**



If undelivered please return to :

**Samrat Pharmachem Limited**

Plot No. A2/3445,

GIDC, Phase 4,

Ankleshwar - 393 002,

Gujarat.